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ABSTRACT
Perfluoroalkyl substances (PFAS), a family of environmental toxicants, are
ubiquitous in the environment and the human population. PFAS are manmade
chemicals that have been widely used in manufacturing since the 1940s. PFAS
are extremely resistant to degradation leading to their accumulation within the
environment and the general population. The most concentrated PFAS member
present in the general population, perfluorooctanesulfonic acid (PFOS), has
been linked to suppressed vaccine response, high serum cholesterol, low fetal
birth weight, thyroid disease, increased markers of liver injury, and even certain
types of cancers. PFOS was voluntarily phased out of manufacturing due to its
bioaccumulutive and toxic properties by the year 2015. In 2016, the EPA
dramatically lowered the federal health advisory level of PFOS in drinking water
to 70ppt due to the emerging evidence of its toxicity. After the phase out of
PFOS, replacement PFAS members perfluorononanoic acid (PFNA) and
perfluorohexanesulfonic acid (PFHxS) took its place and began to rise in
environmental and human serum concentrations. Currently, there is no federal
health advisory level in place for PFNA or PFHxS. The relative toxicity of these
replacement PFAS compounds is still being evaluated in the literature and by
regulatory officials.
PFAS, including PFOS, PFNA, and PFHxS, are known to augment hepatic lipid
accumulation and steatosis in animal studies. However, there is a lack of
knowledge concerning their potential role in the increasing incidence of
nonalcoholic fatty liver disease (NAFLD) in the global population. It is difficult to

study the potential link between PFAS exposure and NAFLD due to the lack of
an accurate and widely accepted serum biomarker for the NAFLD. PFAS levels
are typically measured through serum samples, however NAFLD is often
diagnosed via liver biopsy. Obtaining human liver biopsy data that is matched
to serum samples characterized for PFAS concentration has proven
prohibitively difficult. The vast majority of studies that have evaluated PFAS
exposure in the liver have utilized standard chow diets, high doses, and acute
exposures. In the human population, NAFLD is most commonly induced by poor
diet and lifestyle over time. The present work aimed to understand how
environmentally relevant exposure to PFAS affect the onset and progression of
NAFLD in the presence of a poor diet over a subchronic or chronic timeframe.
Furthermore, this work sought to uncover the mechanistic drivers of these
PFAS-diet interactions.
In manuscript 1, male C57BL6 mice were fed with either a low fat diet (10% kcal
from fat) or a moderately high fat diet (45% kcal from fat) with or without PFOS
or PFNA 0.0003% w/w in feed for 12 weeks. Proteomics and transcriptomics
were utilized to explore the mechanistic pathways driving the liver pathology.
The aim of this study was to assess and explore the impact of diet-PFAS
interactions on the onset of NAFLD using a subchronic, low-dose PFAS
exposure. In addition, we sought to compare the toxicity of PFOS to the
unregulated PFNA. In manuscript 2, male C57BL6 mice were fed with either a
low-fat diet (11% kcal from fat) or a high fat (58% kcal from fat) high
carbohydrate (42g/L) diet with or without PFOS or PFHxS, in feed (0.0003%

w/w) for 29 weeks. Sera lipidomics, as well as hepatic proteomics, gene
expression, and pathology were used to assess diet-PFAS interactions. The aim
of manuscript 2 was to assess the impact of PFAS-diet interactions on the
progression of nonalcoholic fatty liver (NAFL) to the inflammatory stage,
nonalcoholic steatohepatitis (NASH) using a chronic low-dose PFAS exposure.
Moreover, we compared the relative toxicity of PFOS to an unregulated
replacement, PFHxS.
In manuscript 1, PFASs were augmented the onset of fatty liver only in
combination with a low fat diet. Yet in manuscript 2, PFASs worsened
macrovesicular steatosis and inflammation within the high fat high carbohydrate
diet relative to combination with a low fat diet. Both studies revealed that diet
composition as well as slight alterations in PFAS structure exert significant
influence on PFAS tissue partitioning and excretion, liver pathology, lipids, and
the resulting hepatic biochemical signature. Finally, diet-PFAS interactions may
produce differential outcomes depending on the severity and stage of NAFLD.
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PREFACE
This dissertation was prepared in the style of manuscript format. The contents
are divided into two manuscripts that evaluate the relationship between PFAS
structure, diet, and non-alcoholic fatty liver disease (NAFLD). The first
manuscript explores the interaction between a moderately high fat diet and
PFASs in the liver and investigates further alterations in hepatic response
related to the PFAS functional head group. This was achieved in a C57BL6
mouse model of diet-induced obesity using transcriptomic and proteomic
techniques. This manuscript is the first to confirm the diet specific response to
PFOS in the liver, expand this to PFCAs, and to characterize diet-PFAS effects
on the hepatic signature. The second manuscript focuses on PFAS-diet
interactions in a proinflammatory high-fat high carbohydrate diet and the
additional structural impact of PFAS chain length. This was investigated in
C57BL6 mice utilizing proteomic and lipidomic techniques. This manuscript is
the first to characterize direct PFAS-diet effects on the sera lipidome and direct
serum to liver partitioning. Both manuscripts have been prepared for submission
in Toxicological Sciences.
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ABSTRACT
Perfluoroalkyl substances (PFASs) are a family of toxicants universally detected
in human serum and known to cause dyslipidemia in animals and humans. Nonalcoholic fatty liver disease (NAFLD) is most prevalent form of liver disease in
the United States. This study explored diet-PFAS interactions and their potential
to potentiate NAFLD. Male C57BL6 mice were fed with either a low-fat diet (10%
kcal from fat) or a moderately high fat diet (45% kcal from fat, HFD) with or
without perfluorooctanesulfonic acid (PFOS) or perfluorononanoic acid (PFNA)
at a low dose of 0.0003% w/w in feed for 12 weeks. Livers were excised for
histology

and

quantification

of

PFASs

and

lipids.

Proteomics

and

transcriptomics were utilized to conduct mechanistic pathway exploration. The
HFD increased hepatic steatosis. Surprisingly, PFOS and PFNA protected
against the onset of hepatic lipid accumulation and inflammatory progression in
the high fat diet. Genes and proteins related to lipid metabolism, synthesis,
transport, and storage were modulated by PFAS exposure and further impacted
by the presence of dietary fat. When combined with a high fat diet, PFOS and
PFNA attenuated the onset of NAFLD suggesting that dietary fat impacts the
behavior of PFASs in vivo. Furthermore, both dietary fat content and the
chemical functional head group exerted significant influence on hepatic PFAS
accumulation and the resulting hepatic biochemical signature.
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INTRODUCTION
Non-alcoholic fatty liver disease is described by the American Liver Foundation
(ALF), as the excessive accumulation of fats in the liver in the absence of
alcohol use. NAFLD is a spectrum disease that can be broken down into three
distinct stages. The first hit, called fatty liver, is first diagnosed when the fat
content of the liver accounts for greater than 5-10% of the liver weight
(Diagnosis of NAFLD & NASH | NIDDK). According to the American Liver
Foundation, up to 30 – 40% of adults and 10% of children in the US are currently
afflicted with NAFLD (Liver Disease Statistics - American Liver Foundation). As
a silent disease, fatty liver is difficult to diagnose due to the absence of
symptoms and the lack of both non-invasive and reliable diagnostic tests.
Currently, diagnosis is best achieved through liver biopsy and there remains no
FDA approved drug for treatment (El-Agroudy et al., 2019). While obesity,
metabolic syndrome, and diabetes are all known risk factors for NAFLD, the role
of environmental toxicants as risk factors is not well understood (Duseja and
Chalasani, 2013).
Perfluoroalkyl substances (PFASs) are man-made chemicals used in
manufacturing of Teflon, aqueous film forming foams (AFFF), food packaging,
and stain resistant sprays for their unique surfactant and anti-stick properties
(Buck et al., 2011). These long-chain fluorinated structures are extremely
resistant to degradation leading to their accumulation in water sources, dust,
and even ambient air (Hu et al., 2016; Winkens et al., 2018; Barber et al., 2007).
In a study conducted by the Centers for Disease Control and Prevention (CDC),
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screening of human serum samples in the USA revealed PFASs are detectable
in over 98% of the general population (Calafat et al., 2007). PFASs that have
become ubiquitous include, among others, perfluorooctanesulfonic acid (PFOS)
and perfluorononanoic acid (PFNA) (Kato et al., 2011; Olsen et al., 2017). PFOS
and PFNA are slow to excrete from the human body with half-lives spanning
several years, 5.4 and 4.3 years respectively (Olsen et al., 2007) (Zhang et al.,
2013). Once in the body, PFOS and PFNA distribute mainly to protein rich body
compartments such as serum and liver (Jian et al., 2018). This distribution
pattern leads to relatively high exposure of PFASs to hepatocytes, increasing
potential risk for hepatic toxicity.
While the lifetime effects of chronic PFAS exposure remain uncertain, PFASs
have been associated with the following adverse human health effects: impaired
immune function (Grandjean et al., 2012), elevated serum cholesterol (Nelson
et al., 2010), thyroid disease (Ballesteros et al., 2017), low fetal birth weight
(Shoaff et al., 2018), elevated serum markers of liver injury (Salihovic et al.,
2018), and even kidney and testicular cancer (Nicole, 2013). PFASs are
significantly associated with elevated serum ALT, however, the mechanism of
liver injury remains uncertain. Studies conducted in mice (Wan et al., 2012)(Das
et al., 2017), rats (Curran et al., 2008a), and cynomolgus monkeys (Seacat et
al., 2002) have demonstrated that some PFAS members augment lipid
accumulation and steatosis in the liver at high doses. Likewise, PFASs have
been demonstrated to induce lipid accumulation and perturbed lipid metabolism
in human hepatocytes (Bjork et al., 2011; Rosen et al., 2013). To date there is
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only study concerning the long-term effects of low-level exposure to common
PFASs, in combination with dietary risk factors, and their potential role in the
increasing incidence of NAFLD in the global population (Huck et al., 2018). Huck
et. al. discovered that PFOS exhibited a surprising preventative effect against
fatty liver in the presence of a high fat diet. The present study is the first to
confirm this finding and delve further into the mechanistic drivers of diet-PFAS
interactions.
Understanding the potential health effects of PFAS members plays a vital role
in guiding the federal regulations that determine health advisory levels in
drinking water. Due to emerging toxicity data, the health advisory for PFOS in
drinking water was lowered to 70 ppt in 2016 (US EPA, 2016). This health
advisory level was derived from a no observable adverse effect level (NOAEL)
dose of 0.1 mg/kg/day obtained from rodent toxicity studies evaluating the
effects of PFOS on pup weight and mortality (Luebker, York, et al., 2005;
Luebker, Case, et al., 2005). PFAS manufacturing companies, such as 3M,
have voluntarily removed PFOS from manufacturing. However, PFNA may still
legally be used as a PFAS replacement in manufacturing and consumer
products (Kato et al., 2011). Despite the high potential for similar toxicity, PFNA
remains unregulated at the federal level (Wang et al., 2015). Both PFOS and
PFNA continue to be highly prevalent in humans, wildlife, and the environment
today (Jian et al., 2018). This study investigates the potential consequences of
chronic low-level exposure to PFASs in the diet-induced onset of NAFLD.
Lastly, this work characterizes and compares the hepatic signatures of the
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sulfonic acid, PFOS and the carboxylic acid, PFNA while exploring the
additional impact of diet interactions.

MATERIALS AND METHODS
Animals. The study was conducted at the University of Rhode Island in
accordance with Institutional Animal Care and Use Committee (IACUC).
C57BL6 mice were acquired from Jackson Labs (Bar Harbor, ME USA) at sixweeks-old and were acclimated for two weeks prior to being weight paired and
housed four per cage. The mice were housed in a temperature-controlled room
and kept on a strict 12-hour dark/light cycle with access to food and water ad
libitum. Body weights and food consumption were monitored weekly. Following
12 weeks of diet administration, all mice were anesthetized using isoflurane and
euthanized by cervical dislocation. Tissues were immediately harvested and
snap frozen in liquid nitrogen. Gross liver weight was recorded prior to
sectioning in 10% formalin for histology. The remaining liver was snap frozen
for downstream analysis.

PFOS and PFNA Dosing in Feed. Mice were fed either a 10% kcal, low-fat diet
(LFD, D12450B Research Diets, New Brunswick), or a matched 45% kcal,
moderately high fat diet (HFD, D12451 Research Diets, New Brunswick). Mice
were assigned to diet or diet containing either 0.0003% PFOS or 0.0003%
PFNA and fed ad libitum for 12 weeks. PFOS (catalog # 33829-100mg) and
PFNA (catalog # 394459-5G) chemical stocks were purchased from Sigma7

Aldrich (St. Louis, MO, USA). The resulting treatment groups were as follows:
low fat diet (LFD), high fat diet (HFD), LFD + PFOS (LPFOS), HFD + PFOS
(HPFOS), LFD + PFNA (LPFNA), and HFD + PFNA (HPFNA) with n=8 per
treatment group. The daily exposure to PFAS via diet was roughly
~0.3mg/kg/day based on daily food consumption. In the current EPA health
advisory document for PFOS, 0.3 mg/kg/day was considered a NOAEL dose for
PFOS-induced developmental toxicity.

Hepatic Lipid Isolation and Analysis.

Liver lipids were isolated from

approximately 50 mg of liver tissue using the Folch chloroform-methanol
extraction (Folch et al., 1957). Triacylglyceride (TAG) and total cholesterol, were
measured using kits from Pointe Scientific (Ann Arbor, MI USA). Total nonesterified free fatty acids (NEFA) were quantified using a kit from Wako
Chemicals (Richmond, VA USA). Phospholipids were quantified using the
EnzyChrom phospholipid colorimetric assay kit (BioAssay Systems, Hayward,
CA, USA) according to kit instructions. Liver tissue sections were fixed in 10%
buffered formalin prior to paraffin embedding. Paraffin sections (5 μm) were cut
and stained with hematoxylin and eosin (H&E). Stains and scoring were
conducted by Rutgers University Research Pathology Services (Piscataway,
NJ).

The histopathological classification was made by a board-certified

pathologist. Scores ranged from 0 to 5, with 0 being the least and 5 the most
severe.
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Quantification of PFAS Content in Liver. LC-MS/MS was used to quantify
hepatic PFAS concentrations and to further explore the effect of diet on internal
distribution of PFASs to the liver. PFASs were isolated from liver using an
adapted 3M method published by Chang et. al., 2017 (Chang et al., 2017).
Roughly 100mg of tissue was homogenized in 4X LC-MS grade water spiked
with C9 labeled PFNA (Cambridge Isotope Laboratories, Andover, MA, USA)
and C4 labeled PFOS internal standards (Wellington Laboratories, Ontario,
Canada). Of the homogenate, 250μL was transferred to a new tube containing
10% 1N KOH and digested overnight. Following digestion, 100μL of sample was
combined with 100μL 1N formic acid, 500μL 2N HCL, 500μL saturated
ammonium sulfate, and 5mL LC-MS grade MTBE. The samples were shaken
and then centrifuged for 5 min at 2500 x g. For each sample, 4.5mL of the
organic layer was transferred to a fresh tube and evaporated overnight. The
dried samples were re-suspended in 10mL acetonitrile: water and shaken for
30 mins at room temperature. The samples were filtered through a 0.2μm
syringe filter prior to injection on the instrument. The LC-MS/MS analysis was
run in negative mode on a QTRAP® 4500 LC-MS/MS System. A Waters
XBridge C18 (100mm x 4.6mm, 5μm) column was used. Sample injection
volume was 10μL with a flow rate of 0.6mL/min.

RNA Preparation and Transcriptomics. RNA was isolated from roughly 50mg of
hepatic tissue using the Trizol method. The RNA was quantified and checked
for purity on a ThermoFisher Nanodrop 1000 and diluted with DEPC water to

9

equal concentrations. RNA integrity was measured by Agilent Bioanalyzer using
an Agilent RNA 6000 Nano kit. Only pure, intact RNA samples were used for
downstream analysis, RIN score of ≥ 8. An Affymetrix mouse ST 2.0 global
array (Affymetrix, Waltham, MA, USA) was conducted according to
manufacturer protocols.

The array was conducted by the Genomics Core

Facility at Brown University (Providence, RI). Raw .cel files were uploaded into
the Transcriptome Analysis Console (TAC) version 4.0.1 (ThermoFisher,
Waltham, MA USA). TAC software was used to conduct data normalization,
quality control, and differential expression analysis (GEO accession number
GSE138602). The data was filtered using the criteria of ≥ 1.5-fold change and

p-value < 0.05. Pathway analysis was conducted using the Ingenuity Pathway
Analysis (IPA) database from Qiagen (Krämer et al., 2014). The upstream
analysis feature was used to predict upstream regulators. IPA’s comparison
analysis tool was used to compare predicted activation and inhibition between
treatment groups. In addition to the untargeted global array, a targeted
assessment of key genes was conducted.

QuantiGene Plex Targeted Gene Expression. Targeted gene expression
analysis was conducted using a custom QuantiGene Luminex xMAP gene
expression panel (ThermoFisher, Waltham, MA USA) using 0.5 ug of total RNA
as input and according to the manufacturer’s protocol. Analysis of the multiplex
panel was performed according to the manufacturer’s protocols with mean
fluorescence intensity quantified using a Bio-plex 200 instrument (Bio-rad,
10

Hercules, CA USA). Intensity values were normalized to housekeeper gene
beta-actin (Actb) and converted to fold change relative to the control. Hepatic
genes involved in inflammation, lipid uptake, lipid metabolism, and lipid
regulation were analyzed. Genes of interest in the liver included Acaca, Acot2,
Ccl2, Cd36, Cpt1a, Cpt1b, Csf2ra, Cyp4a14, Ehhadh, Gstm3, Fabp1, Cidea,
Fabp4, Fas, Gapdh, Gclc, Gpam, Gusb, Hmgsc1, IL6, Lpl, Nrf2, Nqo1, Pparα,
Pparγ, Scd1, Slc27a1, Sod1, Srebf1, Tnfα, Actb, Hprt, Ppia, and Ppib
(Supplemental Table 1).

Protein Digestions and SWATH-MS Proteomics. Stock protein samples (5
mg/mL) were diluted to 2.5 mg/mL. Protein (200 µg) was spiked with 2 µg BSA
and denatured with 20 µL dithiothreitol (DTT, 100 mM) at 95°C for 15 min in a
shaking water bath (100 rpm). After denaturation, samples were alkylated in the
dark with 20 µL indole-3-acetic acid (IAA, 200 mM) for 30 min at room
temperature. Subsequently, 40 µL of 50 mM ammonium bicarbonate was added
to each sample was pH was confirmed to be alkaline. Further, TPCK-treated
trypsin (10 µg) was added to samples at a ratio of 1:20 (trypsin:protein) and 150
µL of the resulting solution was transferred into digestion tube (PCT
MicroTubes, Pressure Biosciences Inc., Easton, MA). The barocycler was run
at 50°C, for 90 cycles with 60 sec per pressure-cycle (50 sec high pressure, 10
sec ambient pressure, 25 kpsi). Further, to 145 µL of digested peptide sample,
5 µL of ACN (1:1, v/v containing 5% formic acid) was added to acidify the
samples and quench trypsin reaction. Samples were spun to remove any
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participate and 125 µL supernatant was collected (10000 rpm for 5 min at 10°C).
Subsequently, twenty microliters of the resulting peptide solution was injected
into the analytical column and samples were analyzed using LC-MS/MS.
SWATH-DIA proteomics was conducted as previously published(Jamwal et al.,
2017) The proteomics was run on an Acquity UHPLC HClass system (Waters
Corp., Milford, MA, USA) coupled to a SCIEX 5600 TripleTOF mass
spectrometer (SCIEX, Concord, Canada). The method used a run time of 60
min at 100μL/min and a linear gradient. Global protein changes were assessed
using MaxQuant (Tyanova, Temu, and Cox, 2016) and Perseus (Tyanova,
Temu, Sinitcyn, et al., 2016). Targeted data analysis was conducted on the
opensource software Skyline (MacLean et al., 2010) (MacCoss Lab Software)
and normalized to peptide concentration and BSA spiked control. The mass
spectrometry proteomics data have been deposited to the ProteomeXchange
Consortium via the PRIDE partner repository with the dataset identifier
PXD015977.

Statistical Analysis.

Body weight, tissue weight, and hepatic PFAS

concentrations are shown as mean ± standard error (SEM). Unless otherwise
indicated, data was analyzed using one-way analysis of variance (ANOVA)
followed by Fisher’s LSD test for multiple comparisons where p < 0.05 was
denoted as statistically significant. Calculations were performed using
Graphpad Prism (Graphpad Prism Software for Windows Ver 8.0, La Jolla, CA
USA).
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RESULTS
PFOS and PFNA exert differential effects on white adipose, liver, and body
weight
Mice were weight matched prior to assignment to treatment group. Body, liver,
and WAT weight comparisons between low fat diet (LFD) mice and high fat diet
(HFD) fed mice showed an increase of approximately 41%, 36%, and 144%
respectively (Table 1). Interestingly, both PFOS and PFNA caused significant
modulation of tissue and body weights but the effects differed based on the
compound structure. For example, the LPFOS group produced a 44% increase
in WAT weight while LPFNA treatment resulted in a 44% decrease relative to
the LFD controls. Furthermore, PFNA produced a dramatic change in liver
weight with increases of 155% and 73%, relative to the LFD and HFD control,
whereas PFOS only increased liver weight by 18% and 13% respectively.
Lastly, we observed a significant discrepancy in weight gain between the PFOS
and PFNA treated mice within both diets, with PFNA treated mice gaining
significantly less body weight relative to their PFOS treated counterparts.

Dietary fat has a significant impact on PFAS modulation of hepatic lipid
content
An excess of dietary fatty acids within the liver can augment formation of hepatic
lipid droplets and trigger the onset of hepatic steatosis. To explore the potential
interaction of dietary fat with PFOS and PFNA modulation of hepatic lipid
content, liver lipids were extracted and TAG, FFA, cholesterol, and
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phospholipids were quantified (Figure 1A). Within HFD, PFNA decreased
triglyceride content by 28.4%, relative to the HFD control. Within the LFD, PFOS
and PFNA caused significant decreases in hepatic phospholipid content, by
34.3% and 15.6%. This effect was conserved within the HFD with reduction by
31.6% and 33.6%, respectively. To visualize hepatic steatosis, liver sections
were collected at necropsy and scored by a board-certified pathologist for lipid
accumulation (Table 2).
Representative images using hematoxylin and eosin (H&E) staining for each
treatment group are shown in Figure 1C. Arrows highlight hepatic lipid droplets
indicative of steatosis. The HFD controls exhibited clear macrovesicular
steatosis and overall significantly higher scoring for lipid accumulation when
compared to the LFD control. The LFD controls exhibited healthy liver pathology
with 0% of the mice achieving a lipid accumulation score greater than or equal
to 2. Within the LFD fed groups PFOS and PFNA caused an expected increase
in liver lipid accumulation, with 38% and 50% scoring ≥2. The observed increase
in microvesicular steatosis was significant within the LPFNA group. However,
within the high fat diet PFNA exposure resulted in significantly lower scoring for
liver lipid accumulation when compared to HFD control. Out of 8 mice, 100% of
the HFD controls scored ≥2, whereas only 86% for PFOS and 75% for PFNA.
Visually, there is a clear reduction in macrovesicular steatosis within the HPFOS
and HPFNA treated mice when compared to the HFD controls.
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PFOS and PFNA modulation of the hepatic transcriptome is significantly
affected by the PFAS chemical functional head group.
Hepatic gene expression was explored to determine the consequence of PFOS
and PFNA structure, differing by functional head group, in the liver (Figure 2).
Hepatic RNA was prepared for an untargeted transcriptomic array, detecting
34,472 total genes. Between 1,303 and 1,424 hepatic genes were significantly
modulated (p<0.05) by PFOS or PFNA at least 1.5-fold change. To explore the
top genes impacted by PFAS exposure, the top 5 global genes modulated by
diet-PFAS treatment were identified (Table 3). Cyp2b10, a gene involved in the
oxidation of fatty acids, steroids, and xenobiotics, was the top impacted gene in
3 out of the 4 PFAS groups: LFD vs LPFOS (59.1-fold), LFD vs LPFNA (27.0fold), and HFD vs HPFOS (33.5-fold). Cidea, a gene involved in lipid droplet
enlargement, was heavily modulated by the HPFNA group with a measured
global fold change of 88.1 relative to the HFD control. While the total number of
genes modulated by PFNA or PFOS are similar, the transcriptomic signatures,
as measured by overlap between genes impacted, were remarkably unique.
Moreover, scatter plots directly comparing the log2 of the average signal
intensity for PFOS vs PFNA highlight the structure specific modulation in red
and green.
Within the LFD, structure specific effects were observed. Compared to the LFD,
LPFNA and LPFOS modulated a total of 1405 and 1424 hepatic genes
respectively. Out of the total number of differentially expressed genes, only 799
genes, were shared between PFOS and PFNA. This suggests that there are
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both shared and unique genes modulated by PFOS and PFNA within in the liver.
The top genes induced or repressed within each comparison are summarized
within each box. Figure 2B shows a direct comparison of the average signal
(log2) of LPFNA to LPFOS revealing 260 differentially expressed genes.
Compared to LPFOS, LPFNA upregulated RNA associated genes Ddx3y, Mttq, and Supt4b by 4.7, 3.4, and 2.5-fold. Overall, LPFNA suppressed
keratinization and immune response related genes while upregulating genes
involved in RNA processing and transcription when compared to LPFOS.
Structure dependent effects on hepatic gene expression were more pronounced
within the HFD treatment groups. Out of 1,368 and 1,303 genes modulated by
HFD vs HPFNA and HFD vs HPFOS, only 647 of those genes were conserved
between the treatment groups (Figure 2C). Roughly half of the genes modulated
by PFOS or PFNA were unique to the compound’s functional head group, 656
and 721 respectively. Figure 2D depicts 764 differentially expressed genes
when comparing HPFNA to HPFOS directly. Cidea was the top differentially
expressed gene, induced 73.7-fold times higher within the HPFNA treatment
group compared to HPFOS. Furthermore, HPFNA caused relative induction of
Fabp3, a known fatty acid and potential PFAS uptake transporter, by 52.3-fold
and Spltc3, involved in the rate limiting step of sphingolipid biosynthesis, by
34.5-fold. In contrast, HPFNA reduced expression of Hsd3b5, involved in the
biosynthesis of active steroids, by 21.4-fold in comparison to HPFOS. In
addition, HPFNA reduced the expression of Oatp1a1 and Oatp1a4, known
PFOS uptake transporter genes, by 16.6 and 11.3-fold in comparison to
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HPFOS. These robust changes in expression within the same base diets
confirms a significant and PFAS specific alteration to the hepatic transcriptome,
attributable to the functional head group.

PFOS and PFNA modulation of the hepatic transcriptome is significantly
impacted by dietary fat.
A notable diet effect was observed on hepatic transcriptomic expression. When
comparing the PFOS impacted genes within each diet only 617, less than half
of the total differentially expressed genes, were shared between LPFOS and
HPFOS compared to control diet (Figure 3A). When directly comparing HPFOS
to LPFOS gene expression, 824 differentially expressed genes were identified
(Figure 3B). Cidea, a gene involved in lipid droplet enlargement, was the top
differentially expressed gene, induced 73.7-fold times higher within the HPFOS
treatment group compared to LPFOS. Furthermore, HPFOS caused relative
induction of Fabp3, a known fatty acid and potential PFAS uptake transporter,
by 52.3-fold and Spltc3, involved in the rate limiting step of sphingolipid
biosynthesis, by 34.5-fold. In contrast, HPFOS reduced expression of Hsd3b5,
involved in the biosynthesis of active steroids, by 21.4-fold in comparison to
LPFOS. In addition, HPFOS reduced the expression of Oatp1a1 and Oatp1a4,
known PFOS uptake transporter genes, by 16.6 and 11.3-fold relative to
LPFOS. Overall, diet modulated PFOS induced expression of genes involved in
lipid and PFOS uptake, lipid and steroid synthesis, and lipid droplet
enlargement.
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The pronounced diet effect observed with PFOS exposure was conserved in
the PFNA treated groups. LFD vs LPFNA modulated 824, while HFD vs HPFNA
impacted 787 genes unique to the diet. As measured by scatter plot, the direct
comparison of LPFNA to HPFNA based on the log2 of the average signal
intensity yielded 279 differentially expressed genes. Compared to LPFNA,
HPFNA downregulated RNA genes, Snord92 and Ddx37, by 4.4-fold and
metalloprotease, Adam11 by 2.2-fold. In contrast, HPFNA caused relative
induction of olfactory related genes, Obp2a and Vmn2r109, and the RNA gene,
Traj58, by 4.5, 3.0, and 2.4-fold. Based on the expression data, it is clear that
diet exerted a significant influence on PFAS modulation of hepatic
transcriptome.

PFNA is a potent inducer of lipid metabolism, transport, and accumulation
genes.
Targeted gene expression of key genes involved in lipid metabolism, synthesis,
transport, and oxidative stress was measured (Figure 4). The targeted panel of
hepatic genes, names, and functions is further described in Supplemental Table
1. Within the targeted data compound and diet specific effects between PFOS
and PFNA were observed. In the case of Acaca, PFOS caused a 0.8-fold
reduction in expression yet PFNA caused 1.7-fold induction of the same gene.
(Figure 2B), we observed a clear diet effect for genes such as Lpl and Cidea.
Within the LPFOS treatment group a 3.3-fold induction of Lpl was observed,
however the HPFOS mice exhibited a 7.6-fold induction, over twice that of the
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LPFOS group, despite no observed diet induction within the HFD controls.
Likewise, Cidea showed diet specific effects in both PFOS and PFNA treated
mice. Within the LPFOS group, there was no significant induction of Cidea,
however the HPFOS group experienced an 8.5-fold induction in Cidea. Both
PFOS and PFNA affected lipid homeostasis and oxidative stress related genes
and pathways related to perturbed hepatic lipid content on both a targeted and
global scale. Compared to PFOS, PFNA exposure produced 10 to 100-fold
stronger induction of several genes including Acot2, Cpt1b, and Cidea when
administered at the same dose. Overall, PFNA caused stronger induction of
hepatic genes relative to PFOS.

Diet and PFAS interactions cause differential activation of upstream
transcriptional drivers and downstream pathways that can modulate the
onset and progression of NAFLD.
Looking further into the mechanistic function of the untargeted hepatic genes
perturbed by PFAS exposure, upstream pathway regulators were assessed for
potential activation or inhibition (Figure 4). Both PFOS and PFNA significantly
modulated pathways regulated by Ppar, Pxr, Car, Zbtb, and Ahr. PFOS and
PFNA selectively modulated Pml whereas PFOS exerted no effect on this
pathway. Interestingly, HPFOS and HPFNA mediated stronger induction of
Ppar𝛼𝛼 compared to the HFD controls as well as LPFOS and LPFNA,
respectively. Ppar𝛼𝛼 is a key upstream regulator for lipid homeostasis in the liver
and diet specific modulation of this activator could be a driver for differential
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hepatic lipid outcomes. A diet-specific response was also observed in the
coactivator, Ncoa2. Within the HFD, PFOS and PFNA exposure suppressed
signaling of Ncoa2, whereas in the HFD control and LPFOS, an increased zscore was observed. The data suggest that PFNA and PFOS preferentially
activate or enhance the activity of key upstream pathway drivers, such as Ppar𝛼𝛼,
when combined with a HFD. In addition, activation of Nrf2 was observed only
within the PFNA groups, suggesting structure specific activation. The summary
of key transcriptional drivers in response to PFAS exposure and their impact on
NAFLD progression is summarized in Table 4.
Downstream pathway outcomes were predicted using the core analysis feature
and outcomes were compared using comparison analysis within IPA (Figure 5).
Pathways were assigned a z-score indicating predicated activation or inhibition
based on the number of overlapping differentially expressed and direction of
expression for each pathway. HPFNA exhibited the highest degree of
downstream activity activating competing pathways related to the onset of fatty
liver. HPFNA activated genes involved in lipid accumulation, such as fatty acid
and lipid synthesis, as well as lipid metabolism pathways, including beta
oxidation of fatty acids. HPFOS increased glucose and carbohydrate synthesis
pathways and modulated the activation and quantity of immune cells. LPFOS
and LPFNA led to increased synthesis of fatty acids. In addition, LPFNA
activated the competing pathways of fatty acid uptake and fatty acid
metabolism. The upstream drivers and downstream pathways modulated by
either PFOS or PFNA exert competitive influences on the outcome of hepatic
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lipid accumulation, making the key drivers difficult to interpret. Overall, diet and
PFAS functional head group exerted influence on both upstream transcriptional
drivers and downstream pathway outcomes.

Diet and structure induced alterations in the transcriptomic signatures of
PFOS and PFNA are conserved at the protein level.
Proteomics was performed on mouse hepatic tissue to derive the expression of
>300 hepatic proteins. The global analysis of the liver proteome supports the
diet and compound effects observed in the transcriptomic data. A PCA plot was
generated to visualize changes in the global liver proteome (Figure 7). Distinct
groupings can be observed between treatment groups. Both diet and the PFAS
compound caused distinct shifts in the proteomic signature of the liver.
Interestingly, the federally unregulated PFNA showed a drastic shift in grouping
compared to both PFOS and dietary controls. In Figure 8, the total number of
differentially expressed proteins out of total proteins detected can be found
within the box next to each comparison. Again, both diet and structure
dependent effects on expression were observed. For example, LPFNA
significantly impacted the expression of 197 out of ~300 proteins detected while
LPFOS modulated 65. LPFNA and LPFOS shared 46 proteins, while LPFOS
retained 19 and LPFNA 151 unique changes.
To confirm the global changes observed, targeted quantification of relevant lipid
and oxidative stress related molecules was performed using open source
targeted proteomic analysis software called Skyline (Figure 9). The elevated
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potency of PFNA can be clearly observed at the protein level in the expression
of fatty acid metabolizing, cytochrome P450s, and antioxidant proteins. For the
cytochrome P450s, PFOS exhibited stronger induction for Cyp2c enzymes
including, Cyp2c50 and Cyp2c37. However, PFNA showed more potent
induction for Cyp4a enzymes, Cyp4a12 and Cyp4a14. Lastly, we observed that
the relative induction of gene and protein expression was conserved for many
of the overlapping gene and protein targets such as Ehhdah and Cyp4a14. In
conclusion, both PFOS and PFNA significantly modulated the liver proteome
and potential metabolic function at an exposure relevant dose.

Diet specific modulation of liver pathology in the presence of PFAS could
be attributed to altered expression of PFAS uptake transporters.
Diet exerted a dramatic influence on the resulting liver pathology. A potential
mechanism to explain the paradoxical effect of PFAS in combination with high
fat diet on the onset of fatty liver disease is proposed in Figure 10. PFASs have
low passive permeability and a high (≥ 400) molecular weight. PFAS uptake
into the liver and reabsorption from the kidney is known to be driven by a class
of transporters called organic anion transporter proteins (Oatps). In the liver,
there are four major Oatps that mediate hepatic uptake from the bloodstream:
Oatp1a1, Oatp1a4, Oatp1b2, and Oatp2b1. In the HFD treated groups, Oatp
transporter expression was significantly reduced by PFAS exposure (Figure
10A). To examine if diet influences the uptake of PFOS and PFNA into the liver,
internal hepatic exposure to PFOS and PFNA was quantified by LC-MS/MS
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(Figure 13B). HFD feeding caused a significant decrease in hepatic
concentration of PFOS and PFNA when compared to LFD feeding. In addition,
PFNA achieved significantly higher hepatic concentrations than PFOS within
both the LFD and HFD treated groups when administered at the same dose.
When taken together, these findings suggest that the high fat diet reduced
PFAS accumulation within the liver via decreased uptake transporter
expression.
PFASs are known to interact with not only Oatps but also with fatty acid binding
proteins (Fabps) for transporter mediated uptake. In Figure 6, we observed that
the expression of fatty acid uptake transporters Fabp1, Fabp4, Cd36, and
Slc27a1 was induced by PFAS within both diets. In Figure 4, a notable increase
in Ppar𝛼𝛼 activity within the HFD + PFAS groups can be observed. Ppar𝛼𝛼
activation leads to the downregulation of Oatps. This diet specific
downregulation coupled with an elevated influx of dietary fatty acids from the
HFD into the serum may lead to increased competition between PFASs and
FFAs for hepatic uptake. This competitive uptake could lead to a decrease in
both lipid and PFAS accumulation in the liver.

DISCUSSION
The majority of studies examining PFAS induced hepatic steatosis utilize
relatively high doses of PFAS, acute exposure windows, and a standard diet
(Wan et al., 2012; Kudo et al., 2006; Bagley et al., 2017; Curran et al., 2008b).
It has been well-established that a high dose of PFASs can incite the onset fatty
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liver when administered with a lean standard mouse chow (Armstrong and Guo,
2019). However, the mechanism of this toxicant associated fatty liver disease
(TAFLD) is still poorly understood. The current theories include PFAS induced
choline deficiency (Zhang et al., 2016), impaired mitochondrial function (Quist
et al., 2015; Yao et al., 2016), and impaired lipid export via VLDL (Bijland et al.,
2011; Wang et al., 2014). PFAS exposure is lifelong and there is a need to better
understand the potential hepatotoxicity of PFAS under chronic exposure to
environmentally relevant doses. Moreover, the largest risk factor for NAFLD is
metabolic syndrome, often initiated by poor diet. In order to better explore the
ability of PFAS to augment NAFLD risk, the experimental design must take into
account the most common risk factor for fatty liver, diet induced metabolic
syndrome.
Only one paper published to date examines a direct sub-chronic NOAEL
exposure to PFAS, in combination with dietary fat on the development of hepatic
steatosis. According to Huck et al., high fat diet feeding in combination with
0.0001% PFOS (~0.1mg/kg/day) resulted in a paradoxical effect against hepatic
lipid accumulation (Huck et al., 2018). Currently, there is no study to date that
has confirmed this contradictory finding or further explored the potential
mechanistic cause. Using a NOAEL dose of 0.0003% PFAS in diet
(~0.3mg/kg/day), this study confirms that co-administration with a high-fat diet
can attenuate low-dose PFOS induced hepatic lipid accumulation. In addition,
this effect was observed using a carboxylic acid containing PFAS member,
PFNA, for the first time. Finally, this work goes further to characterize diet effects
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on hepatic PFAS accumulation and utilizes ‘omics techniques to uncover the
mechanistic drivers of the diet specific response to PFAS exposure.
In the present study, we observed significant PFAS effects on mouse body,
white adipose tissue, and liver weight. PFAS are well-known to reduce body and
white adipose tissue weight, while inducing liver weight at higher doses in
rodents. However, the dose administered in this study was too low to observe
significant PFOS effects on these endpoints. In a study of PFOS exposure to
dams at 0.3mg/kg/day there was similarly no effect on gross weight outcomes,
whereas significant changes were observed at the high dose of 3mg/kg/day
(Wan et al., 2014). Despite administration at the same low dose, PFNA
exposure resulted in significant modulation to body, WAT, and hepatic weights.
PFNA has been previously reported to cause marked hepatomegaly at higher
doses, more so than structurally similar perfluorinated carboxylic acids (PFCAs)
(Kudo et al., 2006). However, the potency of PFNA on gross body and tissue
weights was surprising given the use of an environmentally relevant dose.
PFAS are well known to cause dyslipidemia in rodents as well as humans. In
rodents PFAS are known to cause accumulation of hepatic TAGs, increased
hepatic lipid deposition, and hypocholesterolemia. Interestingly, we observed
significant attenuation of hepatic phospholipid content by PFOS and PFNA
within the LFD and HFD. Phospholipids are known to have a hypolipidemic
effect within the liver and have even been used to attenuate fatty liver disease
(Gundermann et al., 2016). The implication of PFAS reduction in hepatic
phospholipids and its implications in hepatic steatosis has not been adequately
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explored. Phospholipids are known to predict PFAS partitioning and the ability
of phospholipids to bind to PFASs has been confirmed (Dassuncao et al., 2019;
Sanchez Garcia et al., 2018). Phospholipids act as a surfactant to stabilize lipid
droplets, are the major constituent of cell membranes, and aid in vesicle
formation for lipid export. Moreover, an atypical reduction in TAG content was
produced by PFNA and PFOS supplementation within the HFD. This result
supports the histopathology showing significant reduction in hepatic lipid
accumulation with co-administration of PFAS and a high fat diet. This is the
second study to report that a sub-chronic environmentally relevant dose of
PFOS attenuates high fat diet induced hepatic steatosis. Furthermore, this is
the first paper to demonstrate this effect using a PFCA. Our group went further
to quantify the hepatic concentration of PFASs within each treatment group and
characterize their biochemical signatures. Interestingly, we observed significant
reduction in hepatic PFAS concentration with administration of a high fat diet.
There is developmental study that reports a high fat diet significantly increased
hepatic PFAS concentrations in pups with perinatal exposure to PFASs via
dams (Wang et al., 2014).The present work uncovers a novel finding, with direct
PFAS exposure diet modulates the partitioning or excretion of PFASs to
decrease deposition within the liver. Lastly, we confirmed previous reports that
PFNA has more bioaccumulative potential within the murine liver when
compared to the sulfonic acid, PFOS.
The mechanism of diet-PFAS interactions has not been adequately explored.
The previously published work suggests that the driver of the diet specific
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response is differential regulation of Ppar𝛾𝛾 and its down-stream target, Cd36.
However, in the current study no diet specific response in Ppar𝛾𝛾 nor the fatty
acid uptake transporter, Cd36, was observed. This finding was confirmed by
western blot (Supplemental figure 2). PFASs are generally accepted to be
robust Ppar𝛼𝛼 inducers and the findings presented here confirm this. Overall,
PFNA was a more potent inducer of Ppar𝛼𝛼 and the overall transcriptome when
compared to PFOS. The hepatic concentrations of HPFNA and LPFOS were
very similar suggesting that increased transcriptional and protein level
expression induced by PFNA is not entirely dependent on the increased hepatic
deposition. The increased hepatic uptake could be in part due to the PFNA
specific induction of Fabp4, a potential PFAS uptake transporter. This potent
effect on both gene and protein level expression suggests that PFNA may
produce hepatotoxic outcomes at lower doses than PFOS and therefore may
require stricter regulation. Moreover, diet imposed significant influence on the
overall hepatic signatures for both PFOS and PFNA. Ppar𝛼𝛼 induces the
metabolic breakdown of fatty acids and is known to have a protective effect
against the onset of NAFLD. PFASs has been shown to reduce the expression
of Oatps via Ppar𝛼𝛼 mediated suppression (Cheng and Klaassen, 2008). Oatps
are known transporters of PFASs and have been demonstrated to mediate
PFAS deposition and reabsorption. Furthermore, both PFASs and fatty acids
are known to interact with Fabp transporters for hepatic uptake. The decreased
expression of a primary PFAS transporter coupled with increasing competition
between free fatty acids and PFASs for uptake could present a novel
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mechanism for the underlying cause of the diminished hepatic deposition of
both lipid and PFASs within the high fat diet treatment groups.

CONCLUSIONS
Using a diet-induced obesity rodent model, we sought to explore the potential
role of diet in PFOS and PFNA induced fatty liver disease. Despite the lack of
federal regulation, PFNA was significantly more potent than PFOS in altering
hepatic molecular pathways and exhibited increased hepatic deposition. These
findings suggest that PFNA may require stricter regulation than PFOS despite
its structural similarity. Importantly, dietary fat exhibits a prominent influence on
PFAS hepatic accumulation, pathology, and biochemical pathways. This effect
may be caused by Ppar𝛼𝛼 mediated suppression of PFASs uptake transporters,
Oatps. Further studies are warranted to further confirm and explore PFAS-diet
interactions and their potential implications in assessing internal exposure and
risk in human populations.
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FIGURE LEGENDS
Figure 1. Dietary fat determines PFOS and PFNA modulation of hepatic
lipids. 1A.) Lipid moieties were quantified from hepatic lipid extracts and
normalized to liver weight, expressed as mg/g. Statistical significance was
calculated using one-way ANOVA where *: significant from the LFD control, #:
significant from the HFD control, $: significance between PFOS and PFNA
within each diet and &: significance between diet within each compound. 1C.)
Representative H&E stained liver sections. Scores were converted to ranks
prior to significance calculation by one-way ANOVA.
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Figure 2. PFOS and PFNA exhibit diet and structure dependent effects on
the hepatic transcriptome. Global transcriptomic analysis was conducted on
n=3 samples from each group using a Mouse ST 2.0 transcriptomic array from
Affymetrix detecting 34,472 total genes. The data was analyzed using
Transcriptome Analysis Console (TAC) software by Affymetrix. The cutoff
values were set at 1.5-fold change or greater and a p-value < 0.05. The raw
data is available on the GEO database accession # GSE138602. 2A. and 2C.)
Each Ven Diagram shows the overlap between PFOS and PFNA modulated
genes relative to dietary controls. The genes on the left side are the top 10
induced genes, while the genes on the right side are the top 10 suppressed
genes. 2B. and 2D.) Scatter plots were generated using TAC software and show
direct differential expression based on the log2 of the average signal for each
PFOS and PFNA treatment group.

Figure 3. PFOS and PFNA exhibit diet and structure dependent effects on
the hepatic transcriptome. The raw data is available on the GEO database
accession # GSE138602. 3A. and 3C.) Each Ven Diagram shows the overlap
between LFD + PFAS and HFD + PFAS modulated genes relative to dietary
controls. The genes on the left side are the top 10 induced genes, while the
genes on the right side are the top 10 suppressed genes. 3B. and 3D.) Scatter
plots were generated using TAC software and show direct differential
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expression based on the log2 of the average signal for each diet + PFAS
treatment group.

Figure 4. PFOS and PFNA significantly modulate many transcriptional
drivers related to lipid homeostasis within the liver. Upstream analysis was
used to predict transcriptional drivers. Orange signifies activation and blue
signifies predicted upstream regulator inhibition. Activation or inhibited or a
transcriptional regulator was predicted based on the expression state of the
downstream targets and a z-score for activation or inhibition was assigned using
Ingenuity Pathway Analysis software by Qiagen.

Figure 5. PFOS and PFNA significantly modulate many pathways related
to lipid homeostasis within the liver. The color gradient represents IPA
generated pathway inhibition or activation scores, called z-scores. Orange
signifies activation and blue signifies predicted pathway inhibition. Activation or
inhibition of functional pathways was predicted based on the direction of
modulation and the number of genes involved in the pathway.

Figure 6. PFOS and PFNA significantly modulate many gene expression
related to lipid accumulation, metabolism, and oxidative stress on the
targeted level. A targeted Quantigene panel measuring 36 genes was
conducted on a Bioplex 2.0 system. Fluorescence intensity values were
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normalized to beta actin as a housekeeper. The value in each cell represents
the average fold change relative to the LFD control for n=5 samples.

Figure 7. Diet interactions shift the hepatic proteome and PFNA is a potent
modulator. Global protein analysis was conducted using SWATH-MS DIA
proteomics. The raw and processed data is accessible via ProteomeXchange
with identifier PXD015977. The data was analyzed using MaxQuant and
Persues software. The data was filtered for contaminants and the cutoff for
significance was set as p<0.05. The principal component analysis was created
using Perseus software and represents the treatment effect on global hepatic
protein expression.

Figure 8. Structure specific interactions shift the hepatic proteomic
signature of PFNA and PFOS. Each Ven Diagram depicts the overlap between
the significantly modulated proteins from each treatment group. Significance
was calculated on the SWATH-MS acquired data using MaxQuant software.

Figure 9.

PFOS and PFNA significantly modulate protein expression

related to lipid accumulation, metabolism, and oxidative stress on the
targeted level. SWATH DIA-acquisition files were imported into Skyline
(MacCoss Lab Software) for targeted protein expression analysis. Each protein
expression values represents the average expression of two library matched
peptides normalized to nanodrop concentration and beta-actin digestion
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controls. Average expression intensity (n=5) was converted to fold change and
presented in each cell. Orange indicates activation, whereas blue indicates
inhibition relative to control.

Figure 10. Mechanistic drivers of PFAS-diet interactions. Significance was
calculated using one-way ANOVA followed by Fisher’s LSD test. *, p<0.05,
significance from the LFD controls. #, p<0.05, significance from the HFD
controls. $, p<0.05, significance between PFOS and PFNA within the same diet
(i.e. L/HPFOS vs L/HPFNA). &, p<0.05, significance between diet treatment
within the same compound (i.e. LPFAS vs HPFAS). 10A.) Expression is
presented as the log2 of the average signal ± SEM. The values were generated
via transcriptomic array on n=3 individual samples per treatment group. 10B.)
Male C57BL6 mice were fed with either a low fat diet or a moderately high fat
diet with or without PFOS or PFNA (0.0003% w/w in feed) for 12 weeks. After
necropsy, PFOS and PFNA were extracted from liver and quantified using LCMS/MS. All control groups exhibited PFOS and PFNA concentrations below the
lower limit of quantification (LLOQ). Likewise, no quantifiable crosscontamination between PFOS and PFNA treated groups was found. All values
are means ± SEM; n = 7-8. 10C.) HPFNA and HPFOS enhanced activity of
Ppar𝛼𝛼 relative to dietary controls and LPFAS groups. Ppar𝛼𝛼 activation causes
a reduction in Oatp expression, a known uptake transporter for PFAS.
Decreased Oatp expression coupled with increased serum free fatty acids

41

(FFAs) from diet creates increased competition for fatty acid uptake
transporters. This competition reduces hepatic FFA and PFAS accumulation.
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TABLES
Table 1. Body and Tissue Weights
Unit

LFD

LPFOS

LPFNA

HFD

HPFOS

HPFNA

Body Weight

g

30.2±1.1

30.6±1.2#&

27.7±0.7#&

42.6±1.4

40.5±0.3*$&

35.0±1.0*$&

WAT Weight

g

0.9±0.2#

1.3±0.1*#$&

0.5±0.1*#$&

2.2±0.1*

2.3±0.1*$&

1.6±0.1*#$&

Liver Weight

g

1.1±0.1

1.3±0.1$

2.8±0.3*#$

1.5±0.1

1.7±0.0$

2.6±0.2*#$

Liver:BW

%

4.4±0.7

4.3±0.1$&

10.2±1.0*#$&

3.4±0.3

4.1±0.1$&

7.4±0.5*#$&

WAT:BW

%

2.9±0.4#

4.3±0.2*#$&

1.7±0.3*#$&

5.3±0.3*

5.7±0.3*$&

4.6±0.2*$&

Weight Gain

%

25.1±4.5

26.8±4.3#$

18.7±1.9#$&

79.1±5.2

66.4±2.6*$&

48.2±7.0*$&

#

#

&

*

*

Male C57BL6 mice were fed with either a low fat diet or a moderately high fat
diet with or without PFOS or PFNA (0.0003% w/w in feed) for 12 weeks. After
euthanization, gross body and organ weights were recorded and analyzed. *,
p<0.05, significant in comparison to the LFD control. #, p<0.05, significant in
comparison to the HFD control. $, p<0.05, significance between PFOS and
PFNA within the same diet (i.e. L/HPFOS vs L/HPFNA). &, p<0.05, significance
between diet treatment within the same compound (i.e. LPFAS vs HPFAS).
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Table 2. Lipid Accumulation Scores
Treatment

LFD

LPFOS

LPFNA

HFD

HPFOS

HPFNA

0

3/8

2/8

0/8

0/8

0/7

0/8

1

5/8

3/8

4/8

0/8

1/7

2/8

2

0/8

3/8

4/8

2/8

3/7

5/8

3
4

0/8
0/8

0/8
0/8

0/8
0/8

5/8
1/8

3/7
0/7

1/8
0/8

%≥2

0%#

38%#&

50%*#

100%*

86%*&

75%*#

The lipid accumulation score assigned out of total mice per group. Assigned
scores ranged from 0 to 4, with 0 being the least and 4 the most severe.
Statistical analysis was performed using Kruskal–Wallis test to derive ranks
followed by Dunn's multiple comparison test for multiple comparisons using
GraphPad Prism software v8.2.0 (La Jolla, CA). *, p<0.05, significant in
comparison to the LFD control. #, p<0.05, significant in comparison to the HFD
control. $, p<0.05, significance between PFOS and PFNA within the same diet
(i.e. L/HPFOS vs L/HPFNA). &, p<0.05, significance between diet treatment
within the same compound (i.e. LPFAS vs HPFAS).
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Table 3. Top Global Hepatic Genes
Gene
Cyp2b10
Cyp2c55
Cyp2c53
Gstm3
Cyp2b13
Cyp2b10
Gstm3
Cyp2c55
Cyp4a12b
Gstt3

L vs LPFOS
Fold
Change
59.14
15.86
9.83
8.79
6.94
H vs HPFOS
33.48
6.76
6.23
4.59
4.33

ANOVA PValue
0.000021
0.000059
0.003011
0.00236
0.039922

Gene
Cyp2b10
Mogat1
Serpinb1a
Gstm3
Slc271

0.000018
0.009034
0.000548
0.000737
0.000259

Cidea
Sptlc3
Fabp3-ps3
Gm15441
Otop1

L vs LPFNA
Fold
Change
26.99
7.06
7.02
6.95
6.45
H vs HPFNA
88.09
42.16
38.98
22.9
11.12

ANOVA PValue
0.005249
0.037019
0.001564
0.003246
0.015992
0.009264
0.000055
0.000156
0.000037
0.00137

Transcriptomic array fold change and p-values were derived from the
Transcriptome Analysis Console (TAC). The top genes were identified through
the use of IPA (QIAGEN Inc.). The top 5 differentially expressed genes are
summarized for each PFAS-diet comparison. Cyp2b10 was the top modulated
gene in 3 out of 4 comparisons.
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Table 4. Effects of Upstream Transcriptional Regulators on NAFLD Onset.

HFD/LFD

Ppara

Zbtb20

Pxr

Car

Ahr

Nrf2

--

++

++

+++

++

++

+++

++

-

LPFOS/LFD
LPFNA/LFD

+

++

+

+

--

HPFOS/HFD

+

+

++

+

--

HPFNA/HFD

+++

--

++

-

---

+

Steatosis

-

+

+

-

-

+

(Kim et
al., 2017)

(Liu et al.,
2017)

(Zhou et
al., 2006)

(Yamazaki
et al.,
2007)

(Wada et
al., 2016)

(Chowdhry
et al., 2010,
2)

+++

Treatment activation or inhibition of upstream regulators based on IPA derived
z-scores using the upstream analysis feature. The number of pluses or minuses
denotes the intensity of activation or inhibition. A blank well indicates no
predicted effect. The impact of pathway activation on the onset or progression
of NAFLD is summarized in the steatosis row. Literature sources are included
below.
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GENE

NAME

FUNCTION

Acaca

Acetyl-CoA Carboxylase Alpha

enzyme that catalyzes the rate-limiting step in fatty acid synthesis

Acot2

Acyl-CoA Thioesterase 2

regulation of lipid metabolism/intracellular levels of free fatty acids

Cd36

Cluster Determinant 36

involved in long chain fatty acid uptake

Cpt1a

Carnitine Palmitoyltransferase 1A

catalyzes mitochondrial uptake of fatty acids for beta-oxidation

Cpt1b

Carnitine Palmitoyltransferase 1B

rate-controlling enzyme of fatty acid beta-oxidation

Ehhadh

Enoyl-CoA Hydratase And 3-Hydroxyacyl CoA
Dehydrogenase

enzyme in fatty acid beta-oxidation pathway

Slc271a

Solute Carrier Family 27 Member 1A

long-chain fatty acid (LCFA) uptake into the cell

Cidea

Cell Death Inducing DFFA Like Effector A

binds to lipid droplets and regulates their enlargement

Fabp1

Fatty Acid-Binding Protein 1

role in fatty acid uptake, transport, and metabolism

Cyp4a14

Cytochrome P450 4A14

oxidation of medium chain fatty acids

Ppar-𝜸𝜸

Peroxisome Proliferator-Activated Receptor
Gamma

nuclear receptor that activates the peroxisomal beta-oxidation pathway
of fatty acids

Csf2r𝜶𝜶

Colony Stimulating Factor 2 Receptor Alpha

cytokine which controls the production, differentiation, and function of
granulocytes and macrophages

Ccl2

C-C Motif Chemokine Ligand 2

chemotactic factor that attracts monocytes and basophils

Tnf-𝜶𝜶

Tumor Necrosis Factor Alpha

cytokine involved in systemic inflammation

Nrf2

Nuclear Factor Erythroid 2–Related Factor 2

transcription activator that up-regulates genes in response to oxidative
stress

Scd1

Stearoyl-CoA Desaturase

involved in fatty acid biosynthesis

Fas

Fatty Acid Synthase

catalyzes fatty acid synthesis

Fabp4

Fatty Acid-Binding Protein 4

role in fatty acid uptake, transport, and metabolism

Lpl

Lipoprotein lipase

functions as a triglyceride hydrolase and ligand for lipoprotein uptake

Hmgcs1

3-Hydroxy-3-Methylglutaryl-CoA Synthase 1

catalyzes the formation of HMG-CoA

Gstm3

GSTM3 glutathione S-transferase mu 3

mediates uptake and detoxification of both endogenous compounds and
xenobiotics

Nqo-1

NAD(P)H Quinone Dehydrogenase 1

involved in detoxification pathways

Gclc

Glutamate-Cysteine Ligase Catalytic Subunit

the first rate-limiting enzyme of glutathione synthesis

Sod1

Superoxide Dismutase 1

eliminates radicals which are toxic to biological systems

Srebf1
Ppar-𝜶𝜶

Sterol Regulatory Element Binding Transcription
Factor 1
Peroxisome Proliferator-Activated Receptor Alpha

transcriptional activator for lipid homeostasis, regulates fatty acid and
cholesterol synthesis
Transcription factor that regulates the beta-oxidation pathway of fatty
acids

Supplemental Table 1.Targeted hepatic genes and function. Genes
included on the QuantiGene targeted expression panel and their function.
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Supplemental Figure 1. Daily food consumption. Food consumption is
expressed as average consumption per mouse per day over time. Each point
represents average food consumed ± SEM. No significant difference in food
consumption was detected between groups.
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Supplemental Figure 2. Cd36 protein level expression. Representative
western blot visually showing the relative Cd36 protein expression between
treatment groups. An equal amount of protein input was loaded into each well.
Relative diet and compound effects were confirmed using n=5 on subsequent
blots normalized to beta actin. Primary Cd36 antibody was diluted 1:1000. The
transferred membrane was incubated in primary antibody overnight at 4°C. Antimouse Licor secondary antibody was used to produce the signal and the image
was captured on an Odyssey CLX imager.
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ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) is most prevalent form of liver
disease, affecting over 30% of Americans. Perfluoroalkyl substances (PFAS)
represent a family of environmental toxicants that have infiltrated the living
world. This study explores diet-PFAS interactions and their potential role in the
increasing global incidence and progression of NAFLD. Male C57BL/6 mice
were fed with either a low-fat diet (11% kcal from fat) or a high fat (58% kcal
from fat) high carbohydrate (42g/L) diet with or without perfluorooctanesulfonic
acid (PFOS) or perfluorohexanesulfonic (PFHxS) in feed (0.0003% w/w) for 29
weeks. Proteomic, lipidomic, and gene expression measurement techniques
were utilized to explore low-dose outcomes and mechanistic pathways. With
administration of a high fat high carbohydrate (HFHC) diet, PFOS and PFHxS
augmented macrovesicular steatosis, indicative of fatty liver. There was a clear
shift in the lipidome of the serum exhibiting changes in phosphatidylcholines,
phosphatidylethanolamines, plasmogens, sphingomyelins, and triglycerides
with PFAS exposure. Finally, chain length exerted significant influence on tissue
partitioning and the resulting hepatic gene and protein signatures of PFHxS and
PFOS in vivo.
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INTRODUCTION
Perfluoroalkyl substances (PFASs) represent a family of man-made fluorinated
chemicals widely used in manufacturing and consumer products since the
1940s. The legacy PFASs are highly resistant to degradation and are slow to
excrete from the human body, with half-lives spanning several years. PFASs
have become ubiquitous within human serum, detectable in over 98% of the
general population (Calafat et al., 2007). Perfluorooctanesulfonic acid (PFOS)
and perfluorohexanesulfonic (PFHxS) are two of the most prevalent PFAS
members detected in humans. PFOS has an 8-carbon (C8) fully fluorinated
backbone while PFHxS is a 6-carbon (C6) PFOS replacement compound. Both
PFOS and PFHxS contain a sulfonic acid headgroup and exhibit long half-lives,
5.4 and 8.5 years respectively (Olsen et al., 2007). PFAS manufacturing
companies had phased PFOS out of production by 2015, however, PFHxS may
still be manufactured today as a replacement. In 2016 the EPA updated the
health advisory level for PFOS to 70ppt in drinking water, based on a NOAEL
dose for developmental toxicity in rodents (0.1mg/kg/day). While there has been
some state level regulation, currently no federal health advisory level for PFHxS
has been released. PFAS exposure is associated with adverse health effects
related to metabolic and immune function including impaired immune response
to vaccination (Grandjean et al., 2012), elevated serum cholesterol (Nelson et
al., 2010), and increased serum marker of liver injury (Salihovic et al., 2018).
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum disease that
poses a significant public health burden, affecting up to one-third of all
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Americans. The first stage of NAFLD, non-alcoholic fatty liver (NAFL), is
characterized by the presence of macrovesicular steatosis within hepatocytes.
The second stage, non-alcoholic steatohepatitis (NASH) is diagnosed by the
presence of hepatic steatosis with inflammation and hepatocyte damage. If the
fibrosis associated with NASH becomes severe enough to impair liver function,
the patient progresses to the final stage known as cirrhosis. Until the patient
loses significant liver function, NALFD is a silent disease that requires an
invasive liver biopsy for definitive diagnosis (de Alwis et al., 2016). The largest
risk factor for NAFLD is believed to be metabolic syndrome, a common health
problem associated with diet-induced obesity. In fact, dietary and lifestyle
changes is the number one recommended treatment option for NALFD patients.
According to the American Liver Foundation, only 20% of patients with NALF
will progress to the inflammatory stage of NASH. The risk factors that determine
patient progression to NASH are not well understood. However, the combination
of complex sugars and fats is known to be pro-inflammatory and has been used
in diet-induced models of in NASH in rodents.
It has been well established in the literature that PFAS can induce hepatic
steatosis in animals when administered with a lean standard mouse chow (Wan
et al., 2012; Kudo et al., 2006; Bagley et al., 2017; Curran et al., 2008). PFASs
are known for their ability to activate and interact with fatty acid binding and
sensing molecules in the body. This is believed to be attributable to their
structural similarity to endogenous fatty acids. In order to better understand the
potential role of PFASs in the progression of NAFLD we must understand how
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PFASs interact with lipids and the liver in the presence of an inflammatory diet.
Published to date, no study has examined the implications of chronic low-dose
PFAS exposure on the diet-induced progression of fatty liver disease. Only a
handful of papers have evaluated high fat diet-PFAS interactions and only two
evaluated liver pathology (Huck et al., 2018; Cho et al., 2016; Rebholz et al.,
2016; Tan et al., 2013; Wang et al., 2011). Only one study to date examines the
effect of chronic NOAEL level exposure to PFOS in the context of NAFLD (Huck
et al., 2018). Huck et. al. evaluated the role of PFOS on the onset of NAFL but
did not examine the progression of simple hepatic steatosis to NASH. The
current study utilizes a model for diet-induced NASH exposure and a subchronic exposure window of 29 weeks to evaluate the role of PFOS and PFHxS
in NASH disease progression. Furthermore, this study is unique in that will
explore the potential chain length effect between PFHxS (C6) and PFOS (C8)
and uses serum lipidomics to evaluate potential serum biomarkers for PFAS
exposure. Few studies have assessed the effect of PFAS on overall lipidomic
changes, and even fewer assessed the additional effect of diet on PFAS
modulation of the blood lipidome. The present study is the first to investigate the
influence of PFAS-diet interactions on the serum lipidome and the relative
partitioning of PFASs between the liver and the serum.

MATERIALS AND METHODS
Animals. The study was conducted at the University of Rhode Island in
accordance with Institutional Animal Care and Use Committee (IACUC). Mice,
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C57BL/6 were acquired from Jackson Labs (Bar Harbor, ME USA) at eight
weeks old. The mice were acclimated for two prior to being weight paired and
housed three per cage in a temperature-controlled room. A strict 12-hour
dark/light cycle was maintained with access to food and water ad libitum. Body
weights, water, and food consumption were monitored throughout the study.
Following 29 weeks of diet and PFAS administration, mice were anesthetized
using isoflurane and sacrificed by cardiac puncture. Gross liver weight was
recorded prior to sectioning in 10% formalin for histology. The remaining tissues
were snap frozen in liquid nitrogen for downstream analysis.

PFOS and PFHxS in Feed. The study design was based on a published model
of diet-induced NASH (Marin et al., 2016). The mice received either a 11% kcal,
low fat diet (LFD) (D12328, Research Diets, New Brunswick), or a 58% kcal,
high fat diet (HFD) (D12331, Research Diets, New Brunswick). The mice that
received a high fat diet were also administered high carbohydrates both through
the sucrose content of the high fat diet and through carbohydrates added to
drinking water at 42g/L (55% fructose : 45% sucrose). The mice were assigned
to either diet alone, as controls, or to diet containing 0.0003% PFOS or 0.0003%
PFHxS. The PFOS and PFHxS chemical stocks were obtained from SigmaAldrich (St. Louis, MO, USA). The resulting treatment groups are as follows: low
fat diet (LFD), high fat high carbohydrate diet (HFHC), LFD + PFOS (LPFNA),
HFHC + PFOS (HPFOS), LFD + PFHxS (LPFHxS), and HFHC + PFHxS (HPFHxS)
at n=6 per treatment group. The daily exposure to PFAS via diet was roughly
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~0.3mg/kg/day. In the current EPA health advisory document for PFOS, 0.3
mg/kg/day is considered a NOAEL dose for PFOS induced developmental
toxicity.

Hepatic Lipid Isolation and Analysis. Liver lipids were isolated for enzymatic kit
based lipid quantification using the Folch chloroform-methanol extraction
method (Folch et al., 1957). Serum and liver triacylglycerides (TAG) and total
cholesterol, were measured using enzymatic kits from Pointe Scientific (Ann
Arbor, MI USA). At the time of necropsy, liver tissue sections taken from the
largest lobe were fixed in 10% buffered formalin. The sections were paraffin
embedded, cut, and stained with hematoxylin and eosin (H&E). Stains and
scoring were conducted by Rutgers University Research Pathology Services
(Piscataway, NJ). Lipid accumulation scores were assigned by a board-certified
pathologist, ranging from 0 to 5, with 0 being the least and 5 the most severe.

Serum Lipid Isolation. Serum liver lipids were isolated for lipidomic analysis
according to the Bligh and Dyer method (Bligh and Dyer, 1959). The lipidomics
was performed at the University of Georgia (Athens, GA). Briefly, blood samples
designated for lipidomics were suspended in 1.25 ml of methanol and 1.25 ml
of chloroform. Tubes were vortexed for 30 s, allowed to sit for 10 min on ice,
centrifuged (300 x g; 5 min), and the bottom chloroform layer was transferred to
a new test tube. The extraction steps were repeated three times and the
chloroform layer combined. A commercial mix of SPLASH Lipidomix internal
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standards (Avanti Polar Lipids, Inc.) were spiked into each sample. SPLASH
Lipidomix Mass Spec standards includes all major lipid classes at ratios similar
to that found in human plasma. The collected chloroform layers were dried
under nitrogen, reconstituted with 50 µl of methanol: chloroform (3:1 v/v), and
stored at 80ºC until analysis. Lipid content was quantified by determining the
level of inorganic phosphorus using the Bartlett Assay (Bartlett, 1959).

Serum Lipidomic Analysis
Lipid extracts (500 pmol/µl) were prepared for ESI-MS/MS by reconstitution in
chloroform: methanol (2:1, v/v). ESI-MS was performed on a 5 µl aliquot of each
sample as previously described (Zhang et al., 2005) using a LCQ Deca ionmass spectrometer (LCQ Finnigan mass spectrometer (Thermo Fisher-Fenning
Institute, CA) with nitrogen drying gas flow-rate of 81/min at 350 ºC and a
nebulizer pressure of 30 psi. The scanning range was from 200 to 1000 m/z in
positive and negative mode for 2.5 min. The mobile phase was acetonitrile;
methanol; water (2:3:1) in 0.1% ammonium formate. Samples were run in
triplicate (n = 3). Lipid extracts were also analyzed using a high resolution LC
linear ion trap-Orbitrap Hybrid MS” (nanoHRLC-LTQ-Orbitrap MS) (Thermo
Scientific, San Jose, CA). Individuals running samples were blinded to sample
conditions. Mass spectra were acquired in the positive ion mode. Mass
spectrometric parameters for lipid extracts were as follows: spray voltage:
3.5/2.5 kV, sheath gas: 40/35 AU; auxiliary nitrogen pressure: 15 AU; sweep
gas: 1/0 AU; ion transfer tube and vaporizer temperatures: 325 and 300/275°C,
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respectfully. Full scan, data-dependent MS/MS (top10-ddMS2), and dataindependent acquisition were collected at m/z 150–2000, corresponding to the
mass range of most expected cellular lipids. Lipids were separated on a
nanoC18 column (length, 130 mm; i.d, 100 µm; particle size, 5 µm; pore size,
150 Å; max flow rate, 500 nL/min; packing material, Bruker Micron Magic 18).
Mobile phase A was 0.1% formic acid/water; mobile phase B was 0.1% formic
acid/acetonitrile. 10 μL of each sample was injected for analysis. A constant
flow rate of 500 nL/min was applied to perform a gradient profiling with the
following proportional change of solvent A (v/v): 0 to 1.5 min at 98% A, 1.5 to
15.0 min from 98% to 75% A, 15.0 to 20.0 min from 75% to 40% A, 20.0 to 25.0
min from 40% to 5% A, 25.0 to 28.0 min kept at 5% A, and 28.0 to 30.0 min from
5% to 98% A. The LTQ-Orbitrap Elite MS was set in the positive full scan mode
within range of 50 to 1500 m/z. Settings of the electrospray ionization were:
heater temperature of 300°C, sheath gas of 35 arbitrary unit, auxiliary gas of 10
arbitrary unit, capillary temperature of 350°C, and source voltage of +3.0 kV.
MS/MS fragmentation was induced using a collision-induced dissociation scan
with a Fourier transform resolving power of 120,000 (transient = 192 ms; scan
repetition rate = 4 Hz) at 400 m/z over 50–1500 m/z. Solvent extraction blanks
and samples were jointly analyzed over the course of a batch (10–15 samples).

Lipidomic Data Processing
Full scan raw data files were acquired from Xcalibur™ (Thermo Fisher
Scientific), centroided and converted to a useable format (mzXML) using
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MSConvert. Data processing and peak area integration were performed using
MZmine (Pluskal et al., 2010) and XCMS (Tautenhahn et al., 2012),resulting in
a feature intensity table. Feature tables and MS/MS data were placed into a
directory for each substrate analyzed. Each folder contained each sample type,
feature tables end in “pos.csv” for positive mode. LipidMatch (Koelmel et al.,
2017) was used to identify features. Peak heights were normalized to a mixture
of deuterium labeled internal standards for each sample (SPLASH®
LIPIDOMIX® Mass Spec standard. Multivariate principal component analysis
(PCA) was performed using MetaboAnalyst 4.0 (http://www.metaboanalyst.ca/).
Automatic peak detection and spectrum deconvolution was performed using a
peak width set to 0.5. Analysis parameters consisted of interquartile range
filtering and sum normalization with no removal of outliers from the dataset.
Features were selected based on a one-way ANOVA analysis and were further
identified using HPLC-MS/MS analysis. Significance for ANOVA plot analysis
was determined based on a fold-change threshold of 2.00, q ≤ 0.05 and p ≤
0.05. Following identification, internal standards were used to normalize each
parent lipid level, and the change in the relative abundance of the lipid species
as compared to its control was determined.

Quantifying Serum and Liver PFAS Content. LC-MS/MS was used to quantify
hepatic and serum PFAS concentrations and to further explore the effect of diet
on internal distribution of PFASs to the liver. PFASs were isolated from liver
using an adapted 3M method previously published (Chang et al., 2017).
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Roughly, 100mg of tissue was homogenized in water spiked PFOS C4 and
PFHxS C3 internal standard. A fraction of the homogenate was digested
overnight in 10% 1N KOH. 100μL of digested sample was mixed with 100μL 1N
formic acid, 500μL 2N HCL, 500μL saturated ammonium sulfate, and 5mL LCMS grade MTBE. For serum PFAS extraction, 20μL of serum was mixed with
200μL of 0.5 M tetrabutylammonium bisulfate, 400μL, 0.25 M sodium
carbonate, internal standard spike, and 3mL of MTBE. For both liver and serum,
the organic layer was transferred to a fresh tube and evaporated to dryness.
The sample was re-suspended in acetonitrile: water and filtered through a
0.2μm syringe filter prior to injection. The LC-MS/MS analysis was conducted
on a QTRAP® 4500 LC-MS/MS System in negative mode using a Waters
XBridge C18 (100mm x 4.6mm, 5μm) column.

RNA Preparation and Expression Measurement. Trizol method was used to
isolated hepatic RNA, quantified by a ThermoFisher Nanodrop 1000 and diluted
with DEPC water to equal concentrations. Gene expression was measured
using a custom QuantiGene Luminex xMAP gene expression panel (Thermo
Fisher, Waltham, MA USA). The assay was conducted on a Bio-plex 200
instrument (Biorad, Hercules, CA USA) according to the manufacturer’s
protocol. The full list of hepatic genes measured, names, and functions can be
found in Supplemental Table 1.

Peptide Preparation and Proteomic Analysis. Hepatic protein samples (500 µg)
were spiked with 2 µg BSA and denatured with 25 µL DTT (100 mM) at 35°C
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for 30 min in a shaking water bath (100 rpm). After denaturation, samples were
alkylated in the dark with 25 µL IAA (200 mM) for 30 min at room temperature.
Samples were subsequently concentrated using the cold water, methanol and
chloroform (1:2:1) precipitation method (centrifugation at 12000 rpm, 5min at
10°C). Protein pellet was washed with ice-cold methanol and then suspended
in 200 µL of 50 mM ammonium bicarbonate (pH 8) containing 3% w/v sodium
deoxycholate (DOC). One hundred of the reduced and alkylated protein sample
was taken for digestion (500 µg protein was taken due to poor pellet formation.
However, only 250 µg protein was digested with trypsin). Further, TPCK-treated
trypsin (10 µg) was added to samples at a ratio of 1:25 (trypsin:protein) and
samples were transferred into digestion tubes (PCT MicroTubes, Pressure
Biosciences Inc.,Easton, MA). The barocycler was run at 35°C, for 90 cycles
with 60 sec per pressure-cycled (50 sec high pressure, 10 sec ambient
pressure, 25 kpsi). Further, 100 µL of digested peptides sample was mixed with
10 µL of ACN (1:1, v/v containing 5% formic acid) to precipitate detergent.
Samples were spun to remove the pellet and 100 µL supernatant was collected
(12000 rpm for 5 min at 10°C). Subsequently, twenty microliters of the resulting
peptide solution were injected on the analytical column and were analyzed using
LC-MS/MS. The SWATH-MS proteomics was conducted on an Acquity UHPLC
HClass system (Waters Corp., Milford, MA, USA) coupled to a SCIEX 5600
TripleTOF mass spectrometer (SCIEX, Concord, Canada). The separation of
the peptides was achieved using a runtime of 60 min at 100 μL/min and a linear
gradient method. The complete description of the method has been previously
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published (Jamwal et al., 2017). Opensource softwares, MaxQuant (Tyanova,
Temu, and Cox, 2016) and Perseus (Tyanova, Temu, Sinitcyn, et al., 2016)
were used to assess global changes and total proteins detected. Skyline
(MacLean et al., 2010) was utilized to determine relative expression for targeted
proteins. For each targeted protein, the peak area of two peptides, represented
by at least three daughter ions and library matched to the parent protein, were
averaged. This peak area was normalized to BSA digestion control as well as
measured sample peptide concentration.

Statistical Analysis. Table values are shown as the average ± standard error
(SEM). Significance was derived using one-way analysis of variance (ANOVA)
followed by Fisher’s LSD test for multiple comparisons where p < 0.05 was
denoted as statistically significant. Statistical tests were performed using
Graphpad Prism (Graphpad Prism Software for Windows Ver 8.0, La Jolla, CA
USA).

RESULTS
Low dose PFHxS augments white adipose weight within a high fat diet.
HFHC feeding caused a 27.4% increase in body weight and 55.7% in liver
weight compared to LFD controls (Table 1). Surprisingly, the LFD significantly
augmented white adipose tissue (WAT): body weight (BW) ratio, by 29.1%
compared to the HFHC treatment controls. Within the LFD, PFOS increased
liver weight by 53.8% and liver:body weight by 61.8% more than its 6 carbon
replacement. Interestingly, PFHxS augmented white adipose weight within the
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HFHC group by 43.7% and 19.4% in comparison to HFHC control and HPFOS
respectively. This is further supported by an observed 37.7% increase in
WAT:BW with HPFHxS administration compared to HFHC control. This finding
is in opposition to the decrease in WAT typically observed in rodent studies
using higher doses of PFOS.

Diet composition exerts a significant impact on hepatic lipid content and
pathology.
An excess influx of dietary lipids and carbohydrates can trigger hepatic lipid
accumulation and the onset of steatosis. Serum and hepatic lipids were
assessed (Figure 1). Food was provided to the mice ad libitum, and
consumption was monitored. Supplemental Figure 1 depicts the average daily
food consumption per mouse over the first 60 days. The LFD mice consumed
significantly more food than the HFHC treatment groups. Furthermore, the
PFAS mice treated mice consumed more food on average than the LFD controls
with LPFOS mice consuming more than LPFHxS. Food consumption among
the HFHC treatment groups was similar. To explore PFAS effects on hepatic
lipids, hepatic and serum total cholesterol and triglycerides were measured
(Figure 1A). Both PFOS and PFHxS caused a significant reduction in total
serum cholesterol compared to the HFHC controls. In addition, PFOS caused a
significant reduction in total serum triglycerides compared to both the HFHC and
LFD controls.
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To visualize liver pathology, liver sections were stained by H&E and scored by
a board-certified pathologist for lipid accumulation, inflammation, and biliary
hyperplasia. Figure 1B depicts a representative image for each treatment group.
The black arrows highlight hepatic lipid droplets indicative of steatosis, as well
as PFAS induced alterations in lipid droplet structure and size. All treatment
groups, including the LFD controls, exhibited macrovesicular hepatic steatosis
consistent with fatty liver disease. The prevalence of fatty liver within the LFD
controls was likely caused by the advanced age of the mice at the time of
necropsy and the significant overconsumption within the LFD groups.
Surprisingly, 50% of both the HFHC and the LFD fed mice scored ≥3 for lipid
accumulation (Table 2). Within the LFD, PFOS and PFHxS reduced this lipid
accumulation with 33% and 0% scoring ≥3. However, PFAS exerted the
opposite effect in the HFHC diet scoring 83% for HPFOS and 100% for
HPFHxS. Visually, there is a clear change in the lipid droplet structure within the
PFAS treated mice when compared to the controls. HPFOS, LPFOS, and
HPFNA increased the relative abundance of microvesicular lipid droplets in
comparison to controls. Inflammation is an important feature of the progression
of NAFL to NASH. Interestingly, diet significantly modulated hepatic
inflammation induced by PFAS, following a similar trend as lipid accumulation
(Table 4). HPFOS and HPFHxS showed significantly increased inflammation
when compared to LPFOS and LPFHxS respectively. Moreover, PFAS
exposure significantly increased biliary hyperplasia within both diets (Table 5).
In summary, PFAS exposure within the HFHC diet significantly augmented the
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severity of inflammation and lipid accumulation when compared to PFAS
exposure within a LFD.

Diet alters partitioning of PFOS and PFHxS between liver and serum.
To examine if diet influences partitioning of PFOS and PFHxS between the
serum and the liver, hepatic and serum PFOS and PFHxS were quantified by
LC-MS/MS (Table 5). PFOS achieved significantly higher cumulative
concentrations, 125.2 and 130.3μg/g, relative to PFHxS at 83.7 and 43.2μg/g
for LFD + PFAS and HFHC + PFAS respectively. In addition, HPFHxS achieved
significantly lower cumulative concentrations than LPFHxS. In the liver, LPFOS
deposition was greater than PFHxS. In the serum, LPFHxS concentration was
over 3 times higher than that of LPFOS. HPFHxS showed a slight elevation in
serum content compared to HPFOS, despite significantly lower total
accumulation. When taken together, these findings suggest that the chain
length of PFOS and PFHxS plays a prominent role in relative distribution
between the serum and liver. Furthermore, diet seems to pose a prominent
influence on PFAS retention and excretion.

Low dose PFOS and PFHxS exposure causes significant untargeted shifts
in the global mouse serum lipidome.
PFAS exposure causes significant dysregulation of the mouse blood lipidome.
Multivariate, unsupervised principal component analysis (PCA) scores plots of
spectral data comparing changes in the blood lipidome after exposure to PFAS
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in the presence of both LFD and HFHC showed distinct clustering. A supervised
PLS-DA of the blood lipidome demonstrated separation between the blood
lipidome of mice exposed to the LFD and the LFD in the presence of both
PFASs (Supplemental Figure 3A). Moreover, similar results were observed for
mice exposed to the HFD and those exposed to the HFD containing both PFASs
(Supplemental Figure 4A). Cross validation values of these PLS-DA models
confirmed discrimination between PFASs in the presence of both LFD and HFD,
with an accuracy value from 0.35 to 0.8 value of R2 Model quality, as evaluated
using R2Y and Q2 values, which reflect the explained fraction of variance and
model predictability (Supplemental Figure 3B, 3C and 4B, 4C). These data
suggest that exposure of mice to both PFASs and diet induce differential
lipidomic profiles within the blood lipidome.

Low dose PFOS and PFHxS exposure causes significant targeted shifts in
the mouse serum lipidome.
Targeted lipidomics was performed to identify specific changes between the
blood lipidome of mice exposed to the LFD and HFHC. Based on the diet-related
comparisons, HPLC-ESI MS/MS was employed to identify the number of
features altered between sample types. Blood from mice exposed to LFD and
HFHC in the presence and absence of PFASs were analyzed using HPLC-ESIOrbitrap-MS/MS and the results were analyzed by a cloud plot analysis (Figure
2). A total of 2,918 dysregulated ion features were identified, encompassing 28
distinct lipid species (Figure 2A). The cloud plot analysis identified several lipids
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that experienced a significant fold-change. The data agree with the above
mentioned ESI-MS analysis supporting the conclusion that PFAS exposure
alters the effect of both LFD and HFHC on the blood lipidome.
Diet-related pairwise comparisons identified 146 dysregulated ion features
between these two groups, as shown by cloud plot (Figure 2B). LC-ESI-MS/MS
analysis of the blood lipidome from mice exposed to the LFD, in comparison to
LPFOS, identified 1,121 dysregulated ion features between these two groups
(Figure 2C). A similar analysis was used to compare changes in the lipidome of
blood isolated from mice exposed to the LFD and those exposed to LPFHxS. A
total of 283 dysregulated ion features were identified between these two groups
(Figure 2D).
A total of 546 dysregulated ion features were identified in blood isolated from
mice exposed to the HFHC in comparison to HPFOS (Figure 2E). A similar
analysis was used to compare changes in the blood lipidome in mice exposed
to HFHC versus HPFHxS. This analysis identified 841 dysregulated ion features
dysregulated between the two groups (Figure 2F). These data were used to
identify the specific lipids altered in the blood of mice exposed to PFASs and to
determine changes in the levels of these lipids.

PFOS

and

PFHxS

significantly

modulate

serum

phospholipids,

triacylglycerdies, and plasmogens in the presence of either a LFD or
HFHC diet.
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Targeted and internal standard validated analysis of the shifted serum lipid
moieties was performed by LC-MS/MS. The HFHC diet significantly modulated
the abundance of serum phosphatidylcholine (PC) moieties relative to the LFD
(Figure 3). Phosphatidylcholine (PC) lipids were enriched in the blood of mice
exposed to LFD + PFAS when compared to LFD controls (Figure 3A). Amongst
the PC lipids, 14:0-22:2 PC was identified as a dominant species enriched in
the blood of mice exposed to LPFOS and LPFHxS diets, as well as HFHC,
relative to LFD controls (Figure 3B). There was significant attenuation of OxPC
in the blood of mice exposed to the HPFHxS diet as compared to the HFHC
alone (Figure 3C). Surprisingly, oxidized lysoPC (OxLPC) was significantly
enriched in the blood of mice exposed to the LPFHxS diet, as compared to the
LFD (Figure 3D). However, there was a significant decrease with LPFOS
compared to LFD. Figure 4 depicts further modulation of phospholipid moieties,
phosphatidylethanolamine (PE), lysoPE (LPE), and their oxidized forms (OxPE
and OxLPE). Within the LFD, levels of phosphatidylethanolamine (PE) were
decreased in the blood of mice exposed to the PFHxS and PFOS (Figure 4A).
Similar results were observed with HPFHxS and HPFOS exposure relative to
HFHC control. Relative to the LFD, partial hydrolysis of PE was attenuated by
LPFHxS, LPFOS, and HFHC (Figure 4B) as determined by decreased
measurement of lysoPE (LPC).
In addition to phospholipids, further modulation of the serum lipidome by PFAS
and diet was observed. Monogalactosyldiacylglycerol (MGDG) levels were
significantly enriched in the blood of mice exposed to the HFHC, as compared
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to the LFD (Figure 5A). Within the HFHC, there was a significant decrease in
mice exposed to PFHxS. The levels of oxidized triacylglycerides (OxTG) were
attenuated in the blood of mice exposed to the LPFHxS and LPFOS relative to
the LFD (Figure 5B). Sphingomyelin (SM) was significantly decreased in the
blood of mice exposed to HFHC as well as those exposed to LPFHxS and
LPFOS diets, as compared to the LFD (Figure 6A). Surprisingly, plasmalogen
levels were increased in the blood of mice exposed to the LPFOS and LPFHxS
diets, as compared to LFD control (Figure 6B). Plasmalogen levels were also
increased in the HPFHxS group as compared to HFHC, yet were decreased in
the blood of mice exposed to the HPFOS diet.
Lipid pathway enrichment analysis (LIPEA) was conducted to identify the top
pathways altered by PFAS and diet. The majority of lipids (50%) altered in
response to either HFHC or PFAS exposure correlated to glycerophospholipid
metabolism (Supplemental Table 2). Other pathways identified included those
mediating sphingolipids, ferroptosis, choline metabolism in cancer, retrograde
endocannabinoid signaling and necroptosis. Overall, PFAS exposure caused
notable shifts in the serum lipidome and diet further influenced PFAS modulated
lipid moieties.

PFOS and PFHxS modulate serum and hepatic lipids via modulation of
hepatic pathways.
The expression of key genes and proteins involved in lipid metabolism,
synthesis, transport, and oxidative stress were measured. The full list of hepatic
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genes, names, and functions is further described in Supplemental Table 1. The
expression data is summarized as fold change relative to either the LFD or
HFHC controls in Figure 6. Overall, PFOS had a more potent effect on hepatic
gene expression. Slc27a1 expression was induced by LPFOS by 2.0 and
HPFOS 2.5-fold compared to 1.2 LPFHxS and 0.9-fold for HPFHxS. The
combination and diet and PFAS chain length also exerted influence over gene
expression. For example, Acaca was highly induced by both PFASs in the LFD
3.3 and 3.6-fold, whereas induction was only 1.1 and 1.5 relative to the HFHC
diet. Gstm3 was significantly repressed 0.2-fold by LPFHxS but not for HPFHxS.
For LPFOS, there was no appreciable effect on Gstm3 expression, yet it was
induced 3.6-fold by HPFOS relative to respective control. Protein level effects
showed similar diet-PFAS specific changes on markers of oxidative stress.
Gstm3 was slightly repressed only by LPFHxS and induced by 3.1-fold by
HPFOS. On the protein level, increased potency of PFOS on is apparent
(Figure 7). Notably, HFHC groups caused stronger induction of several
oxidative stress related proteins including, Ces1, Gstm2, Gstm3, and Gstm7.
The diet specific PFAS modulation of hepatic lipids may be explained by altered
expression of lipid uptake transporters, lipid droplet enlargement protein, and
changes in fatty acid synthesis (Figure 8A). Diet specific induction of fatty acid
uptake transporters, Fabp4 and Cd36, was observed. Increased fatty acid
uptake can promote liver lipid accumulation. Furthermore, we observed
enhanced induction of the fatty acid synthesis gene, Fas and an important
regulator of lipid droplet enlargement Cidea in the HFHC PFOS and PFHxS
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groups specifically. All four genes could have attributed to the increased the
hepatic lipid uptake observed only in the HFHC + PFAS treated groups.
Furthermore, alterations of the serum lipidome may be explained by PFAS and

diet induced changes in the hepatic expression of oxidative stress related and
oxidizing genes (Figure 8B). Nrf2 is a transcription factor that is activated in the
presence of oxidative stress and drives the transcription of antioxidant response
genes. Nrf2 and its target genes Gstm3, Nqo1, and Gclc were upregulated by
the HFHC diet. This enhanced expression could indicate increased oxidation
and oxidative stress in the liver. This elevated oxidative stress in the HFD +
PFAS groups correlates back to the increased presence of oxidized lipid
moieties observed in the serum lipidome.

DISCUSSION
A major limitation of the present study is the overconsumption observed in the
LFD diet groups. It is likely that this overconsumption was the driver of the
induced fatty liver observed in the LFD controls. Furthermore, the mice were at
an advanced age, 39 weeks, at the time of necropsy further contributing to an
elevated risk of metabolic dysfunction. Despite significantly higher consumption
in the LPFOS and LPFHxS groups relative to the dietary control, LPFOS and
LPFHxS caused a counterintuitive protective effect by attenuating the severity
of steatosis and inflammation observed in the control. This low fat diet effect on
liver pathology is similar to the phenomenon observed by Huck et. al, who found
that PFOS exerted a protective effect against diet-induced hepatic steatosis
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within a high fat diet. In contrast, in the present study the HFHC + PFAS groups
actually worsened hepatic lipid accumulation. Perhaps the protective
mechanism of PFASs against hepatic steatosis within a HFD can be
overwhelmed or the addition of high carbohydrates to the drinking water altered
the interaction between PFASs, diet, and the liver. Given the current and
previous findings, it is clear that diet plays a critical role in modulating PFAS
induced NAFLD.
Even taking diet consumption discrepancies into account, it is clear that diet and
structure influenced the overall partitioning of PFASs as well as the retention of
PFHxS. There is very little data available on the relative partitioning of PFASs
between blood and liver in the presence of a HFD. One developmental study
suggests that perinatal exposure followed by HFD consumption later in life
increases hepatic retention of PFOS (Wan et al., 2014). In the present study,
the data suggests that the HFD caused a reduction in hepatic PFAS
accumulation accompanied by increased serum accumulation. Interestingly, the
addition of a HFD reduced the total PFAS concentration suggesting that diet
may modulate the rate of PFAS excretion. This diet effect on excretion could
confound associations between PFAS concentration and NAFLD.
Although a large number of epidemiology studies have examined the potential
for PFASs to induce hepatic steatosis in correlation with other adverse effects,
most of the studies do not evaluate the effect of diet in combination with PFAS
on both the onset and progression of non-alcoholic fatty liver disease (NAFLD).
Further, many studies on blood lipids focus on classical lipid indicators, such as
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cholesterol, LDL, HDL and others. In contrast, few if any, have studied the
ability of PFAS to alter the blood lipidome and correlated these changes to
hepatic steatosis, even fewer have examined the effect of diet on either PFASinduced hepatic steatosis and changes in the blood lipidome.

The present

study represents a first step toward identifying any such correlation. Data from
both untargeted and targeted analysis of the mouse blood lipidome
demonstrated diet-dependent shifts in the types and levels of lipids modulated
by PFHxS and PFOS exposure. This analysis demonstrated that changes in the
lipidome that were dependent on both diet and the presence of PFASs.
Subsequent targeted analysis validated these data and identified the specific
types of lipids altered. These findings are consistent with the previous literature
demonstrating that circulating PC levels were significantly augmented in (nonalcoholic fatty liver (NAFL)) and non-alcoholic steatohepatitis (NASH) patients,
as compared to healthy controls (Tiwari-Heckler et al., 2018) Contrary to PC,
the

level

of

PE,

as

well

as

lysophosphatidylcholine

(LPC)

and

lysophosphatidylethanolamine (LPE) decreased. This trend was also seen in
NAFL and NASH patients in comparison to controls.
Oxidized lipids such as those derived from PC, LPC and TAG have not been
previously associated with PFAS exposure. It is known that oxidized lipids are
not simply by-products formed during lipid peroxidation reactions, but are key
mediators in inflammation (Fu and Birukov, 2009) infection (Matt et al., 2015),
and immune response (Cruz et al., 2008). Furthermore, oxidized lipids are
suggested to be augmented in NASH (Ipsen et al., 2018).
87

Our findings are consistent with previous studies that demonstrate an increase
in plasmalogen levels in steatotic and cirrhotic livers compared to normal livers
(Barr et al., 2012). Elevated plasmalogens are suggested to indicate increased
activity of protective mechanisms against oxidative stress. Furthermore,
plasmalogens are enriched in developing lipoproteins secreted by cultured rat
hepatocytes where they may serve as endogenous plasma antioxidants (Vance,
1990)

However, there are other reports that demonstrate that serum

plasmalogen levels are decreased in patients with NASH and NAFLD as
compared to controls (Puri et al., 2009). A decrease in plasmalogen levels could
be associated with a more severe in NASH patients as opposed to steatosis
patients.
While this study represents the most comprehensive analysis of the effect of
diet and PFAS exposure on the blood lipidome, it is limited as the actual
concentrations for lipid species were not provided. This was in part intentional,
and these data are meant to inspire further studies focusing on the roles of the
specific lipids identified as altered in serum. Furthermore, it is important to point
out that many of these lipids are rather novel and do not have a suitable internal
standard at this time to allow for absolute quantification.

CONCLUSIONS
This study demonstrated that exposure of PFAS in diet alters the effect of LFD
and HFHC on hepatic outcomes and the blood lipidome of mice. This supports
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the hypothesis that the effect of PFAS on lipids in vivo is diet-dependent. In the
presence of a high fat high carbohydrate diet, PFOS and PFHxS worsened
hepatic steatosis via increased the expression of genes involved in fatty acid
uptake, synthesis, and lipid droplet expansion. Our findings are consistent with
previous literature reports that both diet and PFAS can augment lipid outcomes,
and this study provides new evidence that PFOS and PFHxS augment oxidative
stress in the liver and increase oxidized lipid species in the sera. This study
represents the first to characterize diet-PFAS impact on the blood lipidome. The
mechanisms by which PFASs may interfere with blood lipids in humans are not
well understood. These findings suggest a correlation between changes in the
blood lipidome and PFAS induced hepatic steatosis providing a basis for
identification of PFAS related lipid predictors. PFOS distributes to the liver more
efficiently than its 6-carbon alternative PFHxS, yet PFHxS causes stronger
modulation of liver pathology within the low and high fat diets. Overall, both diet
and PFAS chain length exerted notable influence over lipid outcomes, PFAS
partitioning, and PFAS excretion.
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FIGURE LEGENDS
Figure 1. Diet composition determines PFOS and PFHxS effects on
hepatic lipids. Statistical significance was calculated using one-way ANOVA
where *: significant from the LFD control, #: significant from the HFHC control,
$: significance between PFOS and PFHxS within each diet and &: significance
between diet within each compound. A) Lipid moieties were quantified from
hepatic lipid extracts and serum and normalized to liver weight, expressed as
mg/g or blood volume expressed as mg/dL. B) Representative H&E stained liver
sections. Black arrows highlight examples of macrovesicular and microvesicular
hepatic steatosis. Scores were converted to ranks prior to significance
calculation.
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Figure 2. Diet and PFAS cause significant shifts in the global serum
lipidome. Differential cloud plot demonstrating dysregulated lipid features in the
blood of male mice (p < 0.05 threshold, fold change >= 1.5 threshold). Upregulated features (features that have a positive fold change) are graphed
above the x-axis and are shown in green, while down-regulated features
(features that have a negative fold change) are shown in red and are graphed
below the x-axis. Only those features whose levels varied significantly (p < 0.05)
are projected. Rows represents a metabolite feature and each column
represents a sample. Data are indicative of 6 samples per group. A)
Dysregulated lipid features between LFD and LFD with PFAS and HFHC and
HFHC with PFAS. B) Differential expression of lipid features between LFD and
HFHC. C) Dysregulated lipid features between LFD and LPFOS. D)
Dysregulated lipid features between LFD and LPFHxS. E) Dysregulated lipid
features between HFHC and HPFOS. F) Dysregulated lipid features between
HFHC and HPFHxS.

Figure 3. Effect of PFOS and PFHxS on phosphatidylcholine (PC) levels
within a LFD or HFHC diet. Lipidomic analysis was outsourced and performed
using mass spectroscopy equipment at the University of Georgia. *** denotes
p<.001; ** denotes p<.01 and * denotes p<.05. Scatter plots showing levels of
phosphatidylcholines lipid moieties in sera between control and PFAS treated
mice within each diet.
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Figure 4. Effect of PFOS and PFHxS on phosphatidylethanolamine (PE)
levels within a LFD or HFHC diet. Data are indicative of 6 samples per group
and are expressed as the mean ± the SEM (*p < 0.05 **p < 0.01*** p < 0.001)
Normalized peak areas between all cells are shown for A) PC, B) 14.0/22.0
PC, C) OxPC, and D) OxLPC. Each symbol represents an individual lipid feature
as identified by LC-MS/MS.

Figure 5. Effect of PFOS and PFHxS on triacylglycerol levels in the blood
of male C57BL/6 mice exposed to a LFD or HFHC diet. Data are indicative
of 6 samples per group and are expressed as the mean ± the SEM (*p < 0.05
**p < 0.01*** p < 0.001). Each symbol represents an individual lipid feature as
identified by LC-MS/MS. Normalized peak areas between all cells are shown for
A) monogalactosyldiacylglycerol (MGDG) and B) oxidized triacylglycerol
(OxTG). Each symbol represents an individual lipid feature as identified by LCMS/MS. Data are compared based on normalized peak areas.

Figure 6. Effect of PFOS and PFHxS on serum sphingomyelin and
plasmogen levels within a LFD or HFHC diet. Data are indicative of 6
samples per group and are expressed as the mean ± SEM (*p < 0.05
**p < 0.01*** p < 0.001). Each symbol represents an individual lipid feature as
identified by LC-MS/MS. Data are compared based on normalized peak areas.
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Figure 7. PFAS-diet interaction alters hepatic gene expression to
modulate lipids and pathology. A targeted Quantigene panel measuring 36
genes was conducted on a Bioplex 2.0 system. Fluorescence intensity values
were normalized to beta actin as a housekeeper. The value in each cell
represents the average fold change relative to the LFD control for n=5 samples.

Figure 8. PFAS-diet interaction alters hepatic protein expression to
modulate lipids and pathology. Global protein analysis was conducted using
SWATH-MS DIA proteomics on n=5 samples per treatment group. The data
was analyzed using MaxQuant and Persues software. The data was filtered for
contaminants and the cutoff for significance was set as p<0.05. Targeted
relative protein expression was derived Skyline. Each value is the average
expression of two peptides for each parent protein, normalized to spike BSA
control and measured protein input. The value is each cell represents the foldchange value relative to the respective control diet.

Figure 9. PFOS and PFHxS modulate hepatic lipid accumulation and
oxidative stress. Targeted graphs of gene expression data showing average
fold change ± SEM. Statistical significance was calculated using one-way
ANOVA where *: significant from the LFD control, #: significant from the HFHC
control, $: significance between PFOS and PFHxS within each diet and &:
significance between diet within each compound. A) Highlights diet-PFAS
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effects on genes related to lipid accumulation. B) Highlights diet-PFAS effects
on genes related to oxidative stress.
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Table 1. Body and Tissue Weights
Unit

LFD

LPFHxS

LPFOS

HFHC

HPFHxS

42.1±2.5

43.5±1.8

44.5±1.
4#&

53.7±1.8*

56.0±1.5*&

Body
Weight

g

WAT
Weight

g

2.4±0.1

2.3±0.3&

2.4±0.2

2.2±0.1

Liver
Weight

g

2.3±0.3#

2.1±0.2#$

3.3±0.5$

Liver:B
W

%

5.0±0.8

4.7±0.3$

WAT:B
W

%

5.9±0.4#

Weight
Gain

%

60.0±8.3

#

#

#&

3.2±0.2*#$

HPFOS
51.6±2.1*
&

&

2.7±0.2$

3.6±0.2*

3.1±0.5

3.8±0.3*

7.6±1.4#

6.6±0.4

5.7±0.8

7.6±0.3

5.2±0.5

5.4±0.2#

4.2±0.3*

5.8±0.5#

5.2±0.4

61.6±7.8

67.8±4.
3#&

100.7±8.
9*

117.5±7.6

91.9±8.4*

#&

*$&

$&

Male C57BL6 mice were fed with either a low fat diet (LFD) or a high fat high
carbohydrate (HFHC) diet with or without PFOS or PFHxS (0.0003% w/w in
feed) for 29 weeks. After euthanization, gross body and organ weights were
recorded and analyzed. *, p<0.05, significant in comparison to the LFD control.
#, p<0.05, significant in comparison to the HFD control. $, p<0.05, significance
between PFOS and PFNA within the same diet (i.e. L/HPFOS vs L/HPFHxS).
&, p<0.05, significance between diet treatment within the same compound (i.e.
LPFAS vs HPFAS
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Table 2. Lipid Accumulation Pathology Scores
Scores

LFD

LPFHxS

LPFOS

HFHC

HPFHxS

HPFOS

0

0/6

1/5

0/6

0/6

0/6

0/6

1

1/6

1/5

1/6

0/6

0/6

0/6

2

2/6

3/5

3/6

3/6

0/6

1/6

3

3/6

0/5

2/6

3/6

5/6

3/6

4

0/6

0/5

0/6

0/6

1/6

2/6

%≥3

50%

0%#&

33%&

50%

100%*&

83%*&

The lipid accumulation score assigned out of total mice per group. Assigned
scores ranged from 0 to 4, with 0 being the least and 4 the most severe. N =
5-6. Statistical analysis was performed using Kruskal–Wallis test to derive
ranks followed by Dunn's multiple comparison test for multiple comparisons
using GraphPad Prism software v8.2.0 (La Jolla, CA). *, p<0.05, significant in
comparison to the LFD control. #, p<0.05, significant in comparison to the HFD
control. $, p<0.05, significance between PFOS and PFNA within the same diet
(i.e. L/HPFOS vs L/HPFHxS). &, p<0.05, significance between diet treatment
within the same compound (i.e. LPFAS vs HPFAS).
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Table 3. Liver Inflammation Pathology Scores
Treatment
0
1
2
3
4

LFD
0/6
1/6
2/6
3/6
0/6

LPFOS
0/6
1/6
3/6
2/6
0/6

LPFHxS
1/5
1/5
3/5
0/5
0/5

HFHC
0/6
0/6
3/6
3/6
0/6

HPFOS
0/6
0/6
1/6
3/6
2/6

HPFHxS
0/6
0/6
0/6
5/6
1/6

%≥3

50%

33%&

0%#&

50%

83%*&

100%*&

Liver inflammation scores per mouse within each treatment group (n=5-6).
Assigned scores ranged from 0 to 4, with 0 being the least and 4 the most
severe. Scores were converted to ranks using the Kruskal–Wallis test.
Significance was calculated by one-way ANOVA test for multiple comparisons
using GraphPad Prism software v8.2.0 (La Jolla, CA). *, p<0.05, significant in
comparison to the LFD control. #, p<0.05, significant in comparison to the HFD
control. $, p<0.05, significance between PFOS and PFNA within the same diet
(i.e. L/HPFOS vs L/HPFHxS). &, p<0.05, significance between diet treatment
within the same compound (i.e. LPFAS vs HPFAS).
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Table 4. Biliary Hyperplasia Pathology Scores
LFD

LPFOS

LPFHxS

HFHC

HPFOS

HPFHxS

0
1
2
3
4

6/6
0/6
0/6
0/6
0/6

1/6
2/6
3/6
0/6
0/6

3/5
2/5
0/5
0/5
0/5

6/6
0/6
0/6
0/6
0/6

2/6
4/6
0/6
0/6
0/6

1/6
5/6
0/6
0/6
0/6

%≥1

0%

83%*#$

40%$

0%

67%*#

83%*#

The biliary hyperplasia score assigned out of total mice per group. Assigned
scores ranged from 0 to 4, with 0 being the least and 4 the most severe. N =
5-6. Statistical analysis was performed using Kruskal–Wallis test to derive
ranks followed by Dunn's multiple comparison test for multiple comparisons
using GraphPad Prism software v8.2.0 (La Jolla, CA). *, p<0.05, significant in
comparison to the LFD control. #, p<0.05, significant in comparison to the HFD
control. $, p<0.05, significance between PFOS and PFNA within the same diet
(i.e. L/HPFOS vs L/HPFHxS). &, p<0.05, significance between diet treatment
within the same compound (i.e. LPFAS vs HPFAS).
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Table 5. PFOS and PFHxS Partitioning

Liver
(𝛍𝛍g/g)
Serum
(𝛍𝛍g/mL)

LPFHxS

LPFOS

HPFHxS

HPFOS

21.7±1.8$

105.1±15.1$

6.36±1.7$

97.8±7.0$

62.0±5.9$&

20.1±0.0$

36.8±4.3&

32.5±2.1

Male C57BL6 mice were fed with either a low fat diet or a high fat high
carbodydrate diet with or without PFOS or PFHxS (0.0003% w/w in feed) for 12
weeks. After necropsy, PFOS and PFHxS were extracted from liver and serum
then quantified using LC-MS/MS. All control groups exhibited PFOS and PFHxS
concentrations below the lower limit of quantification (LLOQ). Likewise, no
quantifiable cross-contamination between PFOS and PFHxS treated groups
was found. PFHxS partitioned to the serum preferentially in comparison to
PFOS. Calculations were done using a one-way ANOVA followed by Fisher’s
LSD test. All values are means ± SEM; n = 1-6. $, p<0.05, significance between
PFOS and PFNA within the same diet (i.e. L/HPFOS vs L/HPFHxS. &, p<0.05,
significance between diet treatment within the same compound (i.e. LPFAS vs
HPFAS).
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Sample
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35

Absorbance (nm)
0.5182
0.4911
0.4943
0.476
0.5225
0.4909
0.452
0.4813
0.4554
0.4535
0.4478
0.4879
0.4994
0.4782
0.438
0.4867
0.4868
0.4836
0.5636
0.8733
0.8326
0.8272
0.8338
0.8616
0.8574
0.8514
0.852
0.8602
0.7129
0.8195
0.8458
0.8401
0.8537
0.8586
0.8106

Concentration (ug)
2.05
1.91
1.93
1.83
2.07
1.91
1.71
1.86
1.73
1.72
1.69
1.89
1.95
1.84
1.64
1.89
1.89
1.87
2.28
3.86
3.65
3.63
3.66
3.80
3.78
3.75
3.75
3.79
3.04
3.59
3.72
3.69
3.76
3.79
3.54

Supplemental Table 1. Lipid phosphorus assay. Lipids extracted from blood
samples were analyzed for inorganic phosphorus content based on analysis of
standards ranging from 1 ug to 5 ug at λ=590 nm. Concentrations of samples were
diluted to 500 pmol/ul.
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Pathway name

Pathw
ay
lipids

Conv
erted
lipids
(num
ber)

Conver
ted
lipids
(perce
ntage)

Glycerophosph
olipid
metabolism

26

Sphingolipid
metabolism

21

3

21.43

Ferroptosis

11

3

21.43

Sphingolipid
signaling
pathway
Choline
metabolism in
cancer
Retrograde
endocannabinoi
d signaling
Necroptosis

9

3

21.43

5

3

21.43

8

2

14.29

4

2

14.29

Arachidonic
acid metabolism
Linoleic acid
metabolism
alpha-Linolenic
acid metabolism
Glycerolipid
metabolism
Pathways in
cancer
Phosphatidylino
sitol signaling
system
Autophagy animal
Glycosylphosph
atidylinositol
(GPI)-anchor
biosynthesis
Phospholipase
D signaling
pathway
Autophagy –
other

75

1

7.14

C00195,
C00550
C00157

25

1

7.14

C00157

23

1

7.14

C00157

15

1

7.14

C00416

15

1

7.14

C00416

11

1

7.14

C00416

4

1

7.14

C00350

3

1

7.14

C00350

7

1

7.14

3

1

7.14

7

50

106

Convert
ed
lipids
(list)

pvalue

Benjami
ni
correctio
n

Bonferro
ni
correctio
n

C04438,
C00416,
C04230,
C00157,
C00350,
C04233,
C05973
C00195,
C00550,
C12126
C21480,
C21481,
C21484
C00195,
C12126,
C00550
C00416,
C04230,
C00157
C00157,
C00350

####
##

######

######

0.014
5

0.0656

0.4069

0.002
1

0.0148

0.0591

0.001
1

0.0103

0.031

0.000
1

0.002

0.0039

0.016
4

0.0656

0.4595

0.003
7
0.883
7
0.493
9
0.464
9
0.332
8
0.332
8
0.255
9

0.0209

0.1046

0.8837

1

0.5122

1

0.5007

1

0.3727

1

0.3727

1

0.3116

1

0.101
3
0.076
9

0.1575

1

0.1435

1

C00416

0.170
9

0.2278

1

C00350

0.076
9

0.1435

1

Supplemental Table 2. LIPEA pathway analysis. List of results from lipid indicators
LFD and LFD with PFAS (LPFOS and LPFHxS) exposure and HFHC and HFHC with
PFAS (HPFOS and HPFHxS) exposure.
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GENE

NAME

FUNCTION

Acaca

Acetyl-CoA Carboxylase Alpha

enzyme that catalyzes the rate-limiting step in fatty acid
synthesis

Acot2

Acyl-CoA Thioesterase 2

regulation of lipid metabolism/intracellular levels of free fatty
acids

Ccl2

C-C Motif Chemokine Ligand 2

chemotactic factor that attracts monocytes and basophils

Cd36

Cluster Determinant 36

involved in long chain fatty acid uptake

Cidea

Cell Death Inducing DFFA Like Effector A

binds to lipid droplets and regulates their enlargement

Cpt1

Carnitine Palmitoyltransferase 1

catalyzes mitochondrial uptake of fatty acids for beta-oxidation

Csf2r𝜶𝜶

Colony Stimulating Factor 2 Receptor Alpha

cytokine which controls the production, differentiation, and
function of granulocytes and macrophages

Cyp

Cytochrome P450 family

oxidation of fatty acids, xenobiotics, etc.

Ehhadh

Enoyl-CoA Hydratase And 3-Hydroxyacyl
CoA Dehydrogenase

enzyme in fatty acid beta-oxidation pathway

Fabp

Fatty Acid-Binding Protein

role in fatty acid uptake, transport, and metabolism

Fas

Fatty Acid Synthase

catalyzes fatty acid synthesis

Gclc

Glutamate-Cysteine Ligase Catalytic
Subunit

the first rate-limiting enzyme of glutathione synthesis

Gstm3

GSTM3 glutathione S-transferase mu 3

mediates uptake and detoxification of both endogenous
compounds and xenobiotics

Hmgcs1

3-Hydroxy-3-Methylglutaryl-CoA Synthase 1

catalyzes the formation of HMG-CoA

Lpl

Lipoprotein lipase

functions as a triglyceride hydrolase and ligand for lipoprotein
uptake

Mttp

Microsomal triglyceride transfer protein

Important function in the hepatic export of lipid rich particles
such as VLDL

Nqo-1

NAD(P)H Quinone Dehydrogenase 1

involved in detoxification pathways

Nrf2

Nuclear Factor Erythroid 2–Related Factor 2

transcription activator that up-regulates genes in response to
oxidative stress

Ppar-𝜶𝜶

Peroxisome Proliferator-Activated Receptor
Alpha

Transcription factor that regulates the beta-oxidation pathway
of fatty acids

Ppar-𝜸𝜸

Peroxisome Proliferator-Activated Receptor
Gamma

nuclear receptor that activates the peroxisomal beta-oxidation
pathway of fatty acids

Scd1

Stearoyl-CoA Desaturase

involved in fatty acid biosynthesis

Slc271a

Solute Carrier Family 27 Member 1A

long-chain fatty acid (LCFA) uptake into the cell

Sod1

Superoxide Dismutase 1

eliminates radicals which are toxic to biological systems

Srebf1

Sterol Regulatory Element Binding
Transcription Factor 1

transcriptional activator for lipid homeostasis, regulates fatty
acid and cholesterol synthesis

Tnf-𝜶𝜶

Tumor Necrosis Factor Alpha

cytokine involved in systemic inflammation

Supplemental Table 3. Custom Quantigene Panel. Gene names and functions
selected for targeted expression analysis. The chosen genes are involved in lipid
accumulation and transport, lipid metabolism, oxidative stress, and inflammation.
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LPFAS/LFD vs HPFAS/HFD
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LFD vs HFD
B.

110

C.

D.

LFD vs LPFOS

LFD vs LPFHxS
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Supplemental Figure 1. Food consumption over the course of the study.
Statistical significance was calculated using one-way ANOVA where a:
significant from the LFD control, b: significant from the HFHC control, c:
significance between PFOS and PFHxS within each diet and d: significance
between diet within each compound. A) Food consumption is expressed as
average consumption per mouse per day over time. Each point represents
average food consumed ± SEM. B) Overall average food consumption per
group was calculated and used to derive significance values.
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Supplemental Figure 2. Glucose tolerance is modulated by HFHC feeding.
A glucose tolerance test (GTT) was conducted following 25 weeks of PFOS
exposure. After a 6 hr fast, 1 mg/kg glucose was administered via intraperitoneal
injection, and blood glucose was measured after 0, 15, 30, 45, 60, 90, 120, and
150 minutes. GTT data is graphed as blood glucose over time.
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A.

B.

C

Supplemental Figure 3. PFAS induce a unique lipidomic signature relative
to LFD control. A) Supervised Partial Least Discriminant Analyses indicate
discrimination between LFD control and LFD with PFAS compounds based on
the lipidome. B) & C) Cross validation (CV) analyses (10-fold CV method)
indicated moderate to high predictive accuracy.
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A.

B

C

Supplemental Figure 4. PFAS induce a unique lipidomic signature relative
to HFHC control. A) Supervised Partial Least Discriminant Analyses indicate
that it is possible to discriminate between HFHC control and HFHC with PFAS
compounds based on the lipidome. B) & C) Cross validation (CV) analyses (10fold CV method)
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SUMMARY AND CONCLUSIONS
Non-alcoholic fatty liver disease is described by the American Liver Foundation
(ALF), as the excessive accumulation of fats in the liver in the absence of alcohol
use(Liver Disease Statistics - American Liver Foundation). Hepatic steatosis can
trigger liver inflammation and fibrosis, progressing to a disease state known as
non-alcoholic steatohepatitis (NASH). If left unchecked the scarring can progress
to a life-threatening condition known as cirrhosis(Pathophysiology of Non
Alcoholic Fatty Liver Disease). According to the American Liver Foundation, up to
30 – 40% of adults and 10% of children in the US are currently afflicted with
NAFLD (Liver Disease Statistics - American Liver Foundation). This silent
disease is difficult to diagnose due to the absence of symptoms and the lack of
non-invasive and reliable diagnostic tests. Currently, diagnosis is best achieved
through an invasive liver biopsy and no FDA approved drug is available on the
market for treatment (El-Agroudy et al., 2019). While obesity, metabolic
syndrome, and diabetes are all known risk factors for NAFLD, the role of
environmental toxicants as risk factors is not well understood (Duseja and
Chalasani, 2013).
Perfluoroalkyl substances (PFASs), a family of environmental toxicants, have
become ubiquitous in the environment and the human population (Olsen et al.,
2017). These long-chain fluorinated structures are extremely resistant to
degradation leading to their accumulation in water sources, dust, and even
ambient air (Hu et al., 2016; Winkens et al., 2018; Barber et al., 2007). PFASs
that can be detected in up to 98% of the human population include, among

others, perfluorooctanesulfonic acid (PFOS), perfluorohexanesulfonic acid
(PFHxS), and perfluorononanoic acid (PFNA) (Mamsen et al., 2019; Olsen et al.,
2017). PFOS, PFNA, and PFHxS are slow to excrete from the human body, with
half-lives spanning several years (Li et al., 2018; Zhang et al., 2013). Once in the
body, these PFASs distribute mainly to protein rich body compartments such as
serum and liver (Bogdanska et al., 2011). This distribution pattern leads to
relatively high exposure of PFASs to hepatocytes, increasing potential risk for
hepatic toxicity. While the lifetime effects of chronic PFAS exposure remain
under investigation, human studies have associated PFAS exposure with
elevated serum cholesterol (Nelson et al., 2010) and biomarkers of liver injury
(Gallo et al., 2012). PFASs have been shown to augment lipid accumulation and
steatosis in the liver in human hepatocytes (Bjork et al., 2011; Rosen et al., 2013)
and rodents (Wan et al., 2012; Das et al., 2017).
There is a clear lack of knowledge concerning the long-term effects of low-level
exposure to common PFASs, in combination with dietary risk factors, and their
potential role in the increasing incidence of NAFLD in the global population
(Younossi et al., 2018). Understanding the potential health effects of PFAS
members plays a vital role in guiding the federal regulations that determine
advisory levels in drinking water. Due to emerging toxicity data, the health
advisory for PFOS in drinking water was lowered to 70ppt in 2016. This health
advisory level was derived from the no observable adverse effect level (NOAEL)
doses observed in rodent toxicity studies evaluating the effect of PFOS on pup
mortality (Drinking Water Health Advisory for Perfluorooctane Sulfonate (PFOS),
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2016). PFAS manufacturing companies, such as 3M, have voluntarily removed
PFOS from manufacturing, however, PFHxS and PFNA are serving as
replacements in manufacturing and consumer products. Despite potential for
similar toxicity, PFHxS and PFNA remain unregulated. Moreover, PFOS, PFNA,
and PFHxS continue to be prevalent in humans, wildlife, and the environment
today (Guelfo et al., 2018). There is a critical need for a better understanding of
PFASs’ hepatotoxicity at an exposure relevant dose.
In Manuscript 1, the subchronic hepatic toxicity of feed containing 0.0003%
PFOS or PFNA was investigated with or without a high fat diet in C57BL6 mice.
Liver pathology was assessed by H&E staining and the hepatic mechanisms
were explored using a combination of transcriptomics and proteomics.
Transcriptomics was performed by ST 2.0 microarray at Brown University.
Transcriptome analysis console (TAC) software from Affymetrix and Ingenuity
Pathway Analysis (IPA) software from Qiagen were used to filter, sort, and
analyze the data. Targeted gene expression was measured using an Affymetrix
Quantigene Plex Panel on a Biorad Bioplex 2.0. Proteomics was performed by
SWATH-MS conducted on a quadrupole-time-of-flight mass spectrometer (ESIQTOFMS). The data was analyzed using proteomic software MaxQuant,
Perseus, and Skyline. LCMS detection of PFASs in serum and liver was
performed in house on a QTRAP® 4500 LC-MS/MS System. In Manuscript 2, the
impact of a high fat and high carbohydrate diet on hepatic steatosis and
progression to NASH in the presence of chronic exposure low dose, 0.0003%
PFOS or PFHxS was assessed. Liver pathology, proteomics, and targeted gene
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expression were performed as they were in Manuscript 1. In addition, shotgun
lipidomics was measured by electrospray ionization-mass spectrometry (ESIMS).
A major take away from the work encompassed is that dietary fat or composition
can dramatically alter the impact that PFASs exert on the onset and progression
of hepatic steatosis and NAFLD. This revelation will be critical to better assessing
the public health risk that PFAS may pose in modulating diet induced fatty liver
disease. The second major conclusion from this work is that the replacement
compounds PFNA and PFHxS produce unique hepatic expression signatures
and partitioning profiles but exert similar effects to PFOS on liver pathology.
Federal health advisories for PFNA and PFHxS have yet to be released, despite
the many structural and behavioral similarities to the known hepatotoxicant
PFOS. The ability of PFOS, PFHxS, and PFNA to significantly alter a disease
outcome at a PFOS non-observable adverse effect level (NOAEL) may be cause
for concern. Given that the replacement compounds, PFHxS and PFNA, do not
seem to mitigate hepatic toxicity in relation to PFOS, it is possible that class level
regulation of the PFAS family may be justified.
The work presented here is focused on characterizing PFAS-diet interactions in
the context of NAFLD. However, the ‘omic (transcriptomic, proteomic, and
lipidomic) data sets that have been generated throughout the course of this work
could serve as a basis to form or answer additional scientific questions outside
the context of NAFLD. The behavior and exact mechanisms of PFAS in vivo
remain poorly understood. Furthermore, these datasets could be re-mined and
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further explored to gain additional insight into the hepatic mechanisms PFAS
modulated NAFLD. For instance, the functional role, biological consequences,
and serum biomarker potential of the identified modulated sera lipid moieties
should be further explored. In addition, the structural similarities and differences
and their mechanistic implications between PFOS and PFHxS or PFOS and
PFNA could be mined further within transcriptomic and proteomic datasets. The
transcriptomic dataset generated in manuscript 1 is available on the GEO
database under accession number GSE138602. The proteomic datasets will be
publicly accessible under the ProteomeXchange Consortium. The manuscript 1
dataset can be found using the identifier PXD015977 and manuscript 2 under
identifier PXD015976. It is my hope that the big data, ‘omic datasets
characterized within may provide a useful springboard for future studies to further
the current understanding of the PFAS family.
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ABSTRACT
Background: A diet rich in fats and sugar can promote obesity, which is linked to
increased systemic inflammation and adverse health outcomes. In the brain, this
inflammatory stimulus activates and promotes recruitment of microglia a key
component in the pathogenesis of neurodegenerative diseases. Poor diet can also
induce and augment the progression of non-alcoholic fatty liver disease (NAFLD)
via

increased

systemic

inflammation,

which

is

also

linked

to

poorer

neurodegenerative outcomes. Pomegranate extract (PE) could be a potential
source of beneficial phytonutrients capable of mitigating these inflammatory
processes.
Methods: Male C57BL/6 mice were fed either a high fat diet (HFD) (45% kcal from
fat) or a standard grain free rodent diet (LFD) (10% kcal from fat) with or without
PE at 1% w/w for 12 weeks. Mice were sacrificed following 12 weeks, and liver
pathology and liver lipid moieties were examined. Whole livers and hippocampi
were excised for multiplexed gene expression analysis of inflammatory, NAFLD,
and neurodegenerative disease associated genes.
Results: Mice fed a HFD for 12 weeks exhibited elevated expression of both proand anti-inflammatory cytokine/growth factors, neurodegenerative genes, and
hepatic lipid associated genes. In mouse hippocampi, HFD+PE mice showed
significant reduction in gene expression of a number of key pro-inflammatory
cytokines such as IL-1α, IL-1β, IL-7, IL-11, TNFα, MAPT, APP, GSK3β, and LEPR.
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In mouse livers, PE significantly reduced lipid accumulation scores and key lipid
regulating genes, such as Cd36, Fas, Acot2, Slc27a1, and Cyp4a14, within a HFD.
Conclusions: In the hippocampus, immune cell recruitment and differentiation for
tissue repair, leptin signaling and neurofibril processing via the MAPT-GSK3β-APP
axis are significantly modulated by PE. In the liver, PE played a preventative role
against the onset and potential inflammatory progression of NAFLD. PE
administration exerted protective effects against lipid accumulation, fatty acid
uptake and metabolism, and hepatic inflammation.

Background
Dietary factors augment the onset and progression of the most common diseases
burdening global health today: type II diabetes mellitus (T2DM), cardiovascular
disease, non-alcoholic fatty liver disease (NAFLD), and numerous forms of
neoplasias (1). Poor diet, such one rich in saturated fats and starches, has been
linked to the generation of low grade inflammation systemically, exerting adverse
effects on multiple organ systems within the body(2,3). The most common liver
disease, NAFLD, and neurodegenerative diseases, such as Alzheimer’s, share
obesity as a risk factor (4,5). Treatments for these diet-associated disorders
include lipid/cholesterol reducers such as statins (atorvastatin, simvastatin), insulin
sensitizers such as metformin and thiazolidinediones (e.g. rosiglitazone), alphaglucosidase inhibitors, fibrates, non-steroidal anti-inflammatory drugs (NSAIDs)
and cholinesterase Inhibitors (6–12). These therapies, which are linked to a
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number of undesirable side effects, have been substituted for less detrimental
forms of medicine such as diet restrictions, bariatric surgery, and exercise (6,7).
The progressive loss in neuron function and viability is associated with aging and
neuroinflammation (13). Neuroinflammation is largely governed by microglia, the
resident immune cells of the brain, (14) and has been associated with the etiology
of AD and PD in rodents and patients

(15,16). One common site of

neuroinflammation is the hippocampus, which is responsible for maintaining basic
cognitive function and memory. The hippocampus is one for the first regions of
the brain to be affected by an inflammatory insult (17,18). The hippocampus is also
a major site for the accumulation of neurotoxic neurofibrillary plaques and tangles
(19,20).
Non-alcoholic fatty liver disease (NAFLD), is a spectrum disease that affects over
30% of the American population (21). The onset of fatty liver is believed to be
initiated by an excess of dietary fatty acids. In the presence of hepatic
inflammation, the disease progresses to non-alcoholic steatohepatitis (NASH) and
prolonged inflammation can cause scarring or fibrosis of the liver. In severe cases
there is a life-threatening loss in hepatic function, known as cirrhosis (22). By
feeding mice a diet rich in saturated fats and refined sugars, this diet promotes
physiologic features exemplified by obese individuals consuming a “Western” diet
as seen in North America and Europe (23).
Natural products have been considered for patients with metabolic syndrome
(MetS) on the basis of safety and cost (24–26). Numerous in vitro, in vivo, and
human clinical studies with natural product usage in MetS diseases such as NASH
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have been published. However, the underlying molecular mechanisms of natural
products and traditional herbal medicines (e.g. Ayurveda and traditional Chinese
medicine) are less defined in the brain. Polyphenols, represent a significant portion
of the natural products commonly studied in age-related disease states and cancer
(27–30). One source of these polyphenols is an extract derived from pomegranate
(Punica granatum). A commercially available pomegranate extract (PE), which is
standardized to its major chemical constituent, punicalagin (PA), has also been
studied for its anti-bacterial, anti-inflammatory and anti-diabetic properties (31–34).
PA and its metabolite, ellagic acid (EA), are known to be metabolized by specific
gut microbes and transformed to a class of significantly studied and therapeutically
valuable compounds known as urolithins (35,36). The anti-inflammatory capacity
and mechanisms of PE constituents have also been investigated using an in vitro
model of neurodegeneration with murine microglia and human neurons (37,38).
Our group has previously measured the ability of PE to combat the effects of AD
in an Beta-amyloid transgenic mouse model (39). Herein, the ability of PE to
modulate the pro-inflammatory effects of a western style diet in the brains and
livers of wild type C57BL/6 mice is explored.

Materials and Methods
Animals and study conditions. C57BL/6 mice were acquired from Jackson Labs
(Bar Harbor, ME USA) and acclimated for at least two weeks. Mice were then
weight paired and housed four mice per cage. Mice were housed under 12-hour
light/dark cycles and were allowed to consume food and water ad libitum. Mice
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were fed either a standard grain-free low fat diet (LFD) (n=8) (Research Diets Cat#
D12450B, New Brunswick, NJ), or a high fat diet where 45% of calories were
derived from fat (HFD) (n=8) (Research Diets Cat# D12451, New Brunswick, NJ).
PE was provided by Verdure Sciences and was incorporated directly into
powdered LFD (n=4) or HFD (n=4) (1% w/w). Body weights and food consumption
were monitored weekly. Following 12 weeks of diet administration, all mice were
anesthetized using isoflurane and sacrificed by cervical dislocation. Tissues were
immediately harvested and snap frozen in liquid nitrogen. Brains were separated
into cortex, cerebellum, and hippocampus regions. Gross liver weight was
recorded prior to sectioning in 10% formalin for histology. The remaining liver was
snap frozen for downstream analysis. This study and its protocols were approved
by and conducted in accordance with the University of Rhode Island Institutional
Animal Care and Use Committee (IACUC) (Approval # AN09-07-004).

Hepatic lipid isolation and analysis. Liver lipids were isolated from approximately
50 mg of liver tissue using a chloroform-methanol extraction method described by
(40). Triacylglyceride (TAG) and total cholesterol, were measured using kits from
Pointe Scientific (Ann Arbor, MI USA). Total non-esterified free fatty acids (NEFA)
were quantified using a kit from Wako Chemicals (Richmond, VA USA).

Nucleic isolation from tissue. Whole hippocampi and livers were isolated at the
time of necropsy and snap frozen for nucleic acid isolation. Tissue was
subsequently homogenized in Trizol reagent. Homogenized material was then
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added directly to a Trizol Spin Column (Zymo Research, San Diego, CA USA) to
isolate nucleic acids according to the manufacturer’s protocol. RNA concentration
and quality were then determined using a spectrophotometer (Nanodrop, Thermo
Fisher, Waltham, MA USA)

Gene expression analysis. Gene expression analysis was conducted on RNA
samples using a custom QuantiGene Luminex xMAP Gene Expression panel
(Thermo Fisher, Waltham, MA USA). The multiplex assay was performed
according to the manufacturer’s protocols and mean fluorescence intensity (FI)
was quantified using a Bio-rad Bio-plex 200 instrument (Hercules, CA USA).
Hippocampi genes of interest in inflammatory, neurodegenerative, and antioxidant
response processes were Il-1α, Il-1β, Il-2, Il-3, Il-4, Il-6, Il-7, Il-9, Il-10, Il-11, Il-13,
Il-15, Il-16, Il-18, Il-19, Ifnα, Ifnγ, Tnf, Cd38, Cd70, Fasl, Mif, Csf1, Cd40lg, Lepr,
Cd36, Mapt, Gsk3β, App, Pparγ, Itgam, Sting, Nos2, Sod1, and Nfe2l2. The
expression of transcripts involved in inflammation, lipid uptake, lipid metabolism,
and lipid regulation were measured in whole liver tissue using a second custom
QuantiGene panel. Hepatic genes of interest included Acaca, Acot2, Ccl2, Cd36,
Cpt1a, Cpt1b, Csf2ra, Cyp4a14, Ehhdh, Gstm3, Fabp1, Cidea, Fabp4, Fas,
Gapdh, Gclc, Gpam, Gusb, Mttp, Hmgsc1, IL6, Lpl, Nrf2, Nqo1, Pparα, Pparγ,
Scd1, Slc27a1, Sod1, Srebf1, Tnfα, Actb, Hprt, and Eif3f.

Statistical analysis. All gene expression data shown as mean fluorescence
intensity (MFI) ± standard error (SEM), was analyzed using one-way analysis of
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variance (ANOVA) and Dunnett’s for multiple comparisons. Body weight, tissue
weight, and hepatic lipid data are shown as mean ± SEM and compared for
statistical significance using ANOVA and fisher’s exact test where p< 0.05 was
statistically significant.

Calculations were performed using Graphpad Prism

(Graphpad Prism Software for Windows Ver 8.0, La Jolla, CA USA).

Results
PE supplementation attenuated high fat diet fed white adipose, liver, and
body weight gains.
Final body weights of HFD mice following 12 weeks of a high fat diet exposure
were increased by approximately 12 grams compared to LFD mice (Figure 1A).
Additionally, the HFD induced liver weight by 15% (Figure 1B) and WAT weight by
50% compared to controls (Figure 1C). The HFD-induced increase in weight was
not observed in the HFD-PE mice, which had final weights similar to LFD fed
controls.

PE supplementation decreased hepatic total lipid, triacylglyceride, and nonesterified free fatty acid levels in LFD and HFD mice and improved dietinduced liver injury.
NAFLD is characterized by increased deposition of fats in liver (41), therefore
hepatic lipid content was determined. The HFD increased total hepatic lipid, TAG,
and FFA content significantly compared to LFD controls. Interestingly, the total
lipid, FFA, and TAG content was attenuated in the HFD-PE mice and were similar
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to the LFD controls (Figure 2A). H&E staining revealed that the HFD fed mice
developed marked macrovesicular steatosis, a signature of fatty liver. PE
supplementation within a HFD clearly protected against lipid vacuolization,
resulting in a healthy liver phenotype similar to the LFD controls (Figure 2B).

PE attenuates hepatic expression of key genes involved in the onset and
progression of NAFLD.
PE suppressed the hepatic expression of nuclear receptors, Pparα and Pparγ, as
well as their target genes related to lipid synthesis, transport, and metabolism in
the liver. PE supplementation caused significant suppression of fatty acid
synthesis genes, Fas and Scd1 (Figure 3A). Within both the LFD and HFD, PE
significantly suppressed fatty acid uptake genes, Fabp1 and Slc27a1. Within the
HFD, PE further attenuated fatty acid transporters CD36 and Fabp4 (Figure 3B).
In addition to uptake, PE modulated the mitochondrial fatty acid beta oxidation
pathway. PE administration resulted in suppressed transcription of fatty acid
metabolism associated genes, Cpt1a, Cpt1b, Ehhadh, and Cyp4a14 (Figure 3C).
Furthermore, PE may prevent inflammatory progression of fatty liver via
suppression of hepatic pro-inflammatory genes, Tnfα, IL6, Csf2ra, and Ccl2
(Figure 4D).

PE attenuates the gene expression of key Interleukins and inflammatory
mediators in hippocampi.

142

The HFD fed increased the relative abundance of multiple interleukins (1, 2, 3, 4,
6, 7, 9, 10, 11, 13, 15, 16, 18, 19) and interferons (α and γ) in hippocampus
compared to the LFD diet (Figure 4). Co-treatment of PE and HFD prevented high
fat induction of Il-1α, Il-1β, Il-7, Il-11, and Tnf gene expression in the hippocampi
tissue, yielding expression levels similar to the LFD controls. Interestingly, Il-2, Il3, and Il-13 were upregulated by 29.6%, 30.3% and 114.7% respectively when
comparing HFD to HFD+PE.

PE supplementation modulates Alzheimer ’s disease associated genes but
augments antioxidant response and reactive nitrogen species hippocampal
gene expression in HFD mice.
In this study, the HFD diet elevated the levels of some transcripts commonly
associated with Alzheimer’s disease: microtubule associated protein tau
(Mapt/Tau), glycogen synthase kinase 3 Beta (Gsk3β), and amyloid precursor
protein (App) (Figure 5A). In general, in mice fed HFD-PE, this induction was not
observed, and expression was similar to LFD controls.
The HFD increased Nitric oxide synthase 2 (NOS2) and super oxide dismutase 1
(SOD1) by 76% and 40%, respectively. PE supplementation LFD mice increased
Nos2 gene expression by 43.4% as compared to the LFD control mice (Figure
5A). Another major antioxidant response gene, Nfe2l2 (commonly known as Nrf2),
was upregulated in the hippocampus by 61.1% in HFD fed mice as compared to
LFD controls. The addition to PE to HFD reduced Nrf2 by 32.1% as compared to
HFD controls.
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PE significantly abrogates Leptin Receptor and Fatty acid transport
Receptor, CD36, in Hippocampi of HFD fed mice.
The HFD increased Cd38, Cd70, FAS ligand, Cd40 ligand by approximately 135%,
288%, 185%, and 89% respectively as compared to LFD control mice (Figure 5B).
Macrophage/microglial associated genes, macrophage infiltration factor (MIF) and
colony stimulating factor 1 (CSF1) were also significantly upregulated by 46.4%
and 74.8% respectively in the HFD fed mice. PE supplementation to LFD
increased the hippocampal gene expression of both Mif and Csf1 by 26.2% and
42.7% respectively. Interestingly, leptin receptor and Cd36, two major fatty acid
transport associated genes, were also markedly increased in HFD fed mice by
192.1% and 82.8% respectively. PE supplementation in HFD reduced the gene
expression of Lepr and Cd36 by 41% and 23.7% in the hippocampus respectively.
Moreover, HFD+PE mice decreased Lepr expression to levels similar to LFD
control mice (7.13 MFI ± 0.94).

Discussion
PE reduced diet-induced weight gain. Following 12 weeks of dietary intervention,
body, white adipose tissue, and liver weights were significantly increased as a
result of exposure to high fat diet (45% kCal from fat) as compared to their low-fat
controls (10% kCal from fat). PE supplementation within the HFD (HFD-PE)
suppressed the HFD-related increase in body, liver, and WAT weight, with those
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measures being similar to the LFD controls. These findings are consistent with
previous reports that PE has anti-obesogenic properties (42).
Several groups have demonstrated the hepatoprotective actions of PE against
NAFLD in both rodent and human models(43,44) This study recreated these
findings in a C57BL6/J model and further explored the mechanistic effect of PE on
hepatic gene expression. Previous papers have identified PPARα/PPARγ
modulation by the PE constituent, punicic acid, as the underlying mechanism of
PE’s protective action against metabolic syndrome and NAFLD (45,46) Likewise,
in this study we saw significant down regulation of both PPARγ/PPARα and their
target genes (Cd36, Fabp1, Cpt1a, Cpt1b, Fas, etc.).
One potential mechanism of PE’s protective effect is reduced fatty acid uptake into
the liver. Hepatic fatty acid accumulation is hypothesized to be a critical initiating
event in the pathogenesis of NAFLD (22). PE significantly suppressed fatty acid
uptake genes, Fabp1, Slc27a1, Cd36, and Fabp4, thereby potentially limiting the
hepatic influx of fatty acids. This diminished uptake was also accompanied by a
decrease in fatty acid synthesis gene, potentially further contributing to a hepatic
reduction in free fatty acids. This proposed mechanism is further supported by
diminished hepatic fatty acid content observed in PE supplemented mice
compared to the HFD controls. Furthermore, there was no induction of the
mitochondrial fatty acid beta oxidation pathway, largely regulated by PPARα.
Relative to the HFD, PE actually suppressed genes related to fatty acid
metabolism in the liver mitochondria, such as, Cpt1a, Cpt1b, Ehhadh, and
Cyp4a14, perhaps suggesting that there is no need for compensatory upregulation
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of fatty acid metabolism.

This finding further supports the theory that the

diminished fatty acid content is attributable to decreased uptake and synthesis
rather than induced fatty acid metabolism in PE-supplemented mice.
PE may play a protective role against the inflammatory progression of NAFLD in a
murine model of diet-induced obesity. Poor diet is known to induce a proinflammatory response in the body (2,3) Previous work has clearly demonstrated
the anti-oxidative action of PE in the liver (47,48) Likewise, in this study PE
significantly dampened expression of Nrf2 mediated oxidative stress response
genes. Furthermore, we observed an expected suppression in hepatic proinflammatory genes: Tnfα, IL6, Csf2ra, and Ccl2. The later stages of fatty liver,
NASH and cirrhosis, are known to be inflammation mediated (22). By protecting
against diet-induced pro-inflammatory gene expression in the liver, PE may
suppress hepatic inflammation and therefore reduce the risk of NAFLD
progression.
In the case of neurodegenerative diseases, studies have shown that specific
dietary components may contribute to the weakening of the blood-brain barrier and
ultimately the progressive activation of microglia (23,49). Over time, the capacity
of microglia to respond to pathogen-associated molecules (i.e. lipopolysaccharide
or bacterial DNA) or damage-associated molecules (i.e. nucleic acids from
necrotic/apoptotic cells) weakens and thus to compensate, more macrophages are
recruited further secreting inflammatory mediators (13,14). This

increase of

inflammatory stimuli leads to the necrosis and apoptosis of neurons and depending
on the localization of this degradation, manifests into AD, PD or ALS (50).
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In the hippocampus, inflammatory mediators, Il-1α and Il-1β were elevated in HFD
mice but modulated in PE treated HFD mice. Il-1 is also implicated in signaling for
tissue repair by stimulating helper T-cells (Th17) (51,52). Il-7 which is heavily
involved in B-cell proliferation, T-cell survival, and stimulation of interleukins in
monocytes, was augmented in HFD but abrogated in HFD-PE mice (53,54). Il-11,
which is responsible for protecting epithelial and connective tissue, stimulating
neuronal development, was upregulated in HFD mice but significantly attenuated
in LFD+PE and HFD+PE mice. Tnfα was also significantly overexpressed in HFD
fed mice but also attenuated to levels similar to LFD control mice. These findings
suggest that PE modulates the immune responses associated with prolonged
exposure to a HFD (15,50).
Consistent with findings from other long-term diet-induced obesity rodent studies,
Tau, Gsk3β, and App, were significantly overexpressed in the hippocampi of mice
fed a HFD as compared to mice fed a standard LFD (23,55,56). PE’s effect within
the hippocampus led to the reduction in gene expression of neurotoxic peptides.
Moreover, our previous studies evaluating these same endpoints but in aged,
transgenic β-amyloid producing mice, demonstrated decreasing trends (39).
Interestingly, PE significantly attenuated hippocampal Lepr as compared to HFD
control mice. Apart from supporting cognitive function, Lepr is implicated in
neuronal synaptic plasticity and the food reward response (57). While serum leptin
levels were not measured, literature suggests that low leptin levels in the brain,
particularly in the hypothalamus, signal for an increase in food intake (58–60).
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In the hippocampus, neuroinflammatory and neurodegenerative processes are
heavily influenced by leptin signaling, and, according to Bonda and colleagues, the
result of obesity rather than age (61). Evidence from other in vivo studies suggests
that leptin resistance in Alzheimer’s disease is due to hyperphosphorylation of tau
by GSK3β and aggregation of neurofibrillary tangles (NFTs) (59,60). In
hippocampal neurons, aberrant leptin signaling causes cognitive deficits over time
(60).
The addition of PE to the HFD significantly reduced the expression of these ADassociated genes and significantly modulated Lepr signaling as compared to LFD
control mice. Additional rodent studies are further needed to confirm the
observation that leptin signaling modulation leads to weight loss and an
improvement in neuron health in HFD+PE fed mice.
PE also augmented hippocampal gene expression in PE+LFD mice of Il-1 β, Il-2,
Il-3, Il-13, Il-19, Nos2, Cd38 and Cd70 as compared to LFD mice. Il-1β, is needed
to maintain neuronal synaptic plasticity (51). The expression of the interleukins 2 ,
3, 13, and 19 are observed during an influx and activation of both lymphocytes and
microglia which may be beneficial and prevent neuronal damage (62,63). Despite
gene expression being elevated, actual protein levels may or may not correlate
indicating PE may exert these effects by binding to specific transcription regulatory
factors.
The constituents of pomegranate and related extracts have been previously
evaluated by a number of groups in rodents and humans(64–70). Specifically, PE
is standardized to Punicalagin, a hydrolysable ellagitannin (67). As a result of oral
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administration, Punicalagin is almost entirely metabolized to ellagic acid in the
stomach and further metabolized in the small and large intestine by key gut
microbes (e.g. Gordonibacter urolithinfaciens) into urolithins(65,71,72). Urolithin A
(UA),urolithin B(UB), methyl urolithin A (mUA), methyl urolithin B (mUB), and
several urolithin analogs have been found in rodents and humans following
pomegranate or ellagitannin exposure(36,65,71). However, inter-individual
variations or “metabotypes” in humans due to the presence or absence of urolithin
producing bacteria have been observed(65). More importantly, UA,UB, mUA, and
mUB are the constituents of PE that pass both intestinal and the blood brain
barriers(68,73).
Urolithins play a critical role in modulating, inflammation (systemic and
neuroinflammation), autophagy, cancer, gut integrity(37,38,64,73,74). Previous
studies have shown urolithins role in modulating LPS induced neuroinflammation
in vitro(37,38). Studies have also shown that urolithins alleviate both triglyceride
accumulation in vitro and diet-induced insulin resistance in mice. Taken together,
urolithins could be a major source of the hepatoprotective and neuroprotective
effects observed in this present study.

Conclusions
PE was able to modulate several key inflammatory molecules in the brain
including Il-1α, Il-1β, Il-7, Il-11, Tnf, Mapt, Gsk3β, App and Lepr. PE also exhibited
protective effects on liver pathology and disease associated transcriptional
pathways. PE not only protected against the onset of diet-induced fatty liver within
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a HFD, but showed protective actions against the inflammatory progression of the
disease. Several potential pathways could be involved in the neuroprotective
effects derived from PE consumption including the modulating the Gsk3β-Tau-App
pathway, immune cell recruitment/differentiation, and leptin signaling in the
hippocampi and PPARγ/PPARα signaling in the liver.
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Figure Legends
Figure 1. PE supplementation is protective against HFD mediated obesogenic
effects. Body, white adipose, and liver weight at the time of necropsy. HFD
feeding significantly increased bodywhite adipose tissue weight, and liver weight.
PE supplementation with a HFD caused significant reduction in body weight gain
, WAT weight gain, and liver weight gain. Statistical significance was calculated
using one-way ANOVA with Fisher’s LSD test where p< 0.05 *, p< 0.01 **,
p<0.001***, p<0.0001****.

Figure 2. PE supplementation attenuates HFD-induced hepatic steatosis.
2A.) Lipid content is shown as milligram lipid per gram liver. Statistical
significance was calculated using one way ANOVA with fisher’s LSD test where
p< 0.05 *, p< 0.01 **, p<0.001***, p<0.0001****. 2B.) Representative H&E
stained, formalin fixed hepatic tissue sections. 2C.) H&E stained sections were
scored by a board-certified pathologist from 0 to 4, where 0 is the least and 4 is
most severe. Statistical significance was calculated using ranks by one way
ANOVA with fisher’s LSD. Significance is defined as * significant to the LFD
control and # significant to the HFD control.

Figure 3. PE attenuates hepatic genes involved in fatty acid uptake, betaoxidation, and inflammation. 3A.) PE supplemented mice exhibited reduced
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expression of fatty acid uptake genes, Fabp1 and Slc27a1. Within a HFD, PE
prevented high fat induction of Cd36 and Fabp4. 3B.) Mice fed PE within either a
LFD or HFD presented with reduced expression of fatty acid metabolism genes,
Cpt1 and Cyp4a14. In addition, PE was protective against high fat induction of
Ehhadh and Cpt1b. 3C.) PE supplementation within a HFD significantly
suppressed pro-inflammatory genes, Tnfα, Ccl2, IL6, and Csf2ra. Statistical
significance was calculated using one way ANOVA where p< 0.05 *, p< 0.01 **,
p<0.001***, p<0.0001****.

Figure 4. PE co-administration reduces induction of pro-inflammatory
interleukins in mouse hippocampi. 4A.) HFD mice displayed elevated levels of
pro-inflammatory cytokines and chemotractants. PE supplemented HFD mice
showed reduced IL-1, IL-6, and IL-7 while also increasing anti-inflammatory
cytokines. 4B.) Pro-inflammatory effects of high fat diet consumption are
modulated with the inclusion of PE in feed continued. HFD mice displayed
elevated levels of pro-inflammatory cytokines and chemoattractant. PE
supplemented HFD mice showed reduced IL-11, IL-18, IFNα, and TNF while also
increasing anti-inflammatory cytokines
Statistical significance was calculated using one way ANOVA where p< 0.05 *,
p< 0.01 **, p<0.001***, p<0.0001****.

Figure 5. PE supplementation abrogated AD, macrophage infiltration, and
metabolic syndrome marker genes. 5A.) HFD feeding for 12 weeks increased
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neurodegenerative associated genes including cytotoxic T-cell chemotractants,
and anti-oxidant enzymes. PE supplementation abrogated these AD markers
within a HFD. 5B.) Macrophage infiltration, metabolic syndrome associated
ligand and receptor genes are differentially expressed with and without PE
inclusion. Statistical significance was calculated using one way ANOVA where p<
0.05 *, p< 0.01 **, p<0.001***, p<0.0001****.
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GENE

LFD VS
HFD
(MEAN
DIFF)

p value

p value

HFD VS.
HPE
(MEAN
DIFF)

p value

catalyzes the rate-limiting
step in fatty acid synthesis

0.0141

0.1676

0.0064

0.5068

0.0126

0.2115

regulation of lipid
metabolism/intracellular
levels of free fatty acids

0.0075

0.6943

0.0347

0.0973

0.06115

0.0108

fatty acid uptake

-0.1403

0.0681

0.0931

0.1993

0.3791

0.0005

Cpt1a

catalyzes mitochondrial
uptake of fatty acids for
beta-oxidation

0.2213

0.0709

0.3528

0.0106

0.2979

0.0231

Cpt1b

rate-controlling enzyme of
fatty acid beta-oxidation

0.0012

0.7888

0.0085

0.0929

0.01379

0.0151

Ehhadh

ezyme in fatty acid betaoxidation pathway

0.1890

0.5923

0.5343

0.1534

0.9607

0.022

Slc271a

long-chain fatty acids (LCFA)
uptake into the cell

-0.0033

0.4080

0.0106

0.0223

0.01661

0.0023

-0.0009

0.3480

0.0009

0.3639

-0.00036

0.6984

Acaca
Acot2

Cd36

Cidea

FUNCTION

binds to lipid droplets and
regulates their enlargement

LFD
VS.
LPE
(MEAN
DIFF)

Fabp1

role in fatty acid uptake,
transport, and metabolism

0.5884

0.3717

2.6260

0.0029

2.31

0.0059

Cyp4a14

oxidation of medium chain
fatty acids

0.0560

0.9223

1.7810

0.0126

2.51

0.002

Ppar-g

nuclear receptor that
activates the peroxisomal
beta-oxidation pathway of
fatty acids

-0.0075

0.0641

0.0082

0.0478

0.02648

<0.0001

Csf2ra

cytokine which controls the
production and function of
granulocytes and
macrophages

0.0010

0.5277

0.0032

0.0637

0.004056

0.0244

Ccl2

chemotactic factor that
attracts monocytes and
basophils

-0.0067

0.0136

0.0010

0.6586

0.01109

0.0008
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Tnf-a

cytokine involved in
systemic inflammation

-0.0019

0.0257

0.0005

0.5215

0.003095

0.0018

Nrf2

transcription activator that
up-regulates genes in
response to oxidative stress

0.0222

0.1894

0.0314

0.0767

0.03414

0.0583

Scd1

involved in fatty acid
biosynthesis

-1.1460

0.1022

0.2346

0.7153

2.746

0.0022

-0.0121

0.3359

0.0484

0.0034

0.0688

0.0004

Fas

catalyzes fatty acid
synthesis

Fabp4

role in fatty acid uptake,
transport, and metabolism

-0.0369

0.0287

0.0001

0.9961

0.03848

0.024

Lpl

functions as a triglyceride
hydrolase and ligand for
lipoprotein uptake

-0.0113

0.0384

0.0073

0.1488

0.01553

0.0095

Hmgcs1

catalyzes the formation of
HMG-CoA

-0.1527

<0.0001

0.0173

0.3976

0.1616

<0.0001

-0.0039

0.6496

0.0384

0.0016

-0.01704

0.0729

Gstm3

mediates uptake and
detoxification of xenobiotics
and endogenous
compounds

Nqo-1

involved in detoxification
pathways

-0.0023

0.5287

0.0106

0.0172

0.0164

0.0017

Gclc

the first rate-limiting
enzyme of glutathione
synthesis

-0.1275

0.1265

0.1020

0.2096

0.3717

0.0011

Sod1

eliminates radicals which
are toxic to biological
systems

0.6196

0.2826

2.5100

0.0016

2.152

0.004

Srebf1

transcriptional activator for
lipid homeostasis, regulates
fatty acid and cholesterol
synthesis

0.0651

0.2946

0.0259

0.6674

-0.09265

0.1489

Ppar-a

transcription factor that
regulates the beta-oxidation
pathway of fatty acids

-0.0153

0.8907

0.3676

0.0094

0.4819

0.0021

Mttp

catalyzes the
transport/export of

0.0109

0.8880

0.1074

0.1910

0.208

0.0244
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triglyceride, cholesteryl
ester, and phospholipid
Gpam

catalyzes an essential step
in glycerolipid biosynthesis

-0.0372

0.2691

0.0341

0.3085

0.1669

0.0007

IL6

cytokine involved in
inflammation/maturation of
B cells

0.0001

0.6932

0.0005

0.0025

0.0004

0.0085

Supplemental Table 1. Hepatic multiplex genes, function, and treatment
comparisons. Gene functions for the full plex of hepatic genes are described.
Mean difference and p-value for key treatment comparisons is defined. Statistical
significance was calculated using one way ANOVA.
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GENE

FUNCTION(1–14)

HFD vs.
LFD
(MEAN
DIFF)

p value

HPE vs.
HFD
(MEAN
DIFF)

p value

IL-1α

induce pro-inflammatory cytokines
and differentiate Th17 cells

10.81

<0.0001

-6.425

0.0017

14.72

<0.0001

-6.26

0.0358

stimulate Tregs, T and B effectors,
and NKTs

0.9238

0.0021

0.7429

0.0246

activate basophil and eosinophils,
recruit phagocytic cells

1.708

0.0002

1.013

0.0317

induce Th2 cells, induce tissue
adhesion and inflammation

0.975

<0.0001

0.2917

0.1754

IL-1β
IL-2

IL-3

IL-4

IL-6

infiltration of leukocytes, T-cell and
B-cell differentiation, survival of
cholinergic neurons

2.823

0.0007

-0.7167

0.3802

IL-7

proliferation of B-cells (pre and
pro), T-cell survival, induce
Interleukin synthesis in monocytes

13.22

0.0002

-11.73

0.0012

IL-9

growth factor for T and Mast Cells,
inhibits Th1 cytokines from CD8 Tcells

1.481

0.0003

-0.4917

0.2225

1.245

0.0056

-0.5417

0.2592

3.807

0.0004

-3.687

0.0021

IL-10

IL-11

immunosuppression via APCs or Tcells

growth factor for erythroid,
myeloid and megakaryocyte
progenitors. Protect epithelial and
connective tissue. Inhibits
monocyte and macrophage activity.
Neuronal development
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IL-13

eosinophil and mast cell
recruitment, activation and growth.
MHC II up regulation on B cells

2.025

0.0002

3.9

<0.0001

IL-15

T-cell proliferation and activation
(NKT), maintain CD8 memory,
neutrophil and eosinophil antiapoptosis

6.667

0.026

-1.837

0.5872

major chemotractant for CD4/CD8
T cells, monocytes, mast cells and
eosinophils.

69.56

0.0119

6.75

0.8042

induces IFNγ with IL-12, activates
Th1 or Th2

249

<0.0001

-98.82

0.1221

induce Th2 cytokines, IL-6, TNFa
and IL-10 in monocytes

3

<0.0001

0.733

0.17

viral response via adaptive immune
signaling, stimulate DCs antigen
presentation, macrophage AbDC,
Promote naïve T-cell growth and
tumor /virus cell apoptosis

4.572

0.0022

-2.85

0.0618

Th1 cell cytotoxic response and
differentiation, upregulates MHC I
and II expression, inhibits cell
growth (epithelial), proapoptosis/cell cycle modulation.

1.113

0.006

0.04286

0.9193

pro-inflammatory and
immunosuppressive by initiating or
limiting severity and duration of
inflammatory response.

2.141

0.0004

-1.802

0.0041

aka Protein Tau, leads to the
generation of Tau tangles (immune
reactive peptides)

692.7

0.0076

-780.4

0.0074

neuronal development via neuronal
progenitor differentiation.

751.8

0.0106

-761.5

0.0161

IL-16

IL-18

IL-19

IFNα

IFNγ

TNF

MAPT

GSK3β
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APP

PPARγ

ITGAM

STING

NOS2

SOD1

NFEL2

CD38

CD70

Amyloid Precursor protein,
normally involved in neuronal
plasticity and neuronal
development. Over expression
leads to plaque formation and
microglial activation

5721

0.0057

4883

0.0369

20

0.0073

-2.249

0.7622

leukocyte adhesion, aka
Macrophage Receptor 1,
upregulated by TNF, mediate
complement coated macrophage
uptake of particles for degradation.

90.02

0.0026

-29.37

0.3086

stimulates interferon genes in
response to viral or internal
pathogens (microbial DNA),
localizes with autophagy related
proteins

16.42

0.0032

-3.786

0.518

induced by IFNγ, TNF and IL-1β.
Macrophage associated NO
production, stimulates IL-6 and IL8, stimulate epithelial cell growth

3.604

<0.0001

-0.16

0.7743

6170

0.0038

-3242

0.1289

aka NRF2, interacts with antioxidant response element,
stimulating Phase II anti-oxidant
response enzymes (HO-1 and NQO1)

58.44

0.0001

-49.03

0.0024

TNFa inducible, Dendritic
organization in hippocampal
excitatory neurons, humoral
immune response

70.13

<0.0001

-8.63

0.5228

TNF ligand, activates T and B cells,
improves cytotoxic function of NK
cells, proliferation of CD8 T cells

15.11

<0.0001

-6.3

0.0764

neuronal depression of
inflammation associated with
chronic or acute insult. Glucose
absorption, lipid balance and cell
growth/differentiation

anti-oxidant response by binding to
superoxide radial molecules
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FASL

MIF

CSF1

CD40LG

LEPR

CD36

TNF ligand, forms Death Domain
Complex leading to caspase 8
mediated apoptosis

2.66

0.0002

-1.117

0.1106

Macrophage Migration Inhibitor
Factor, response to bacterial
infection (LPS or DNA), stimulates
cytokine release in macrophages

1824

0.008

-936.9

0.1819

Colony Stimulating Factor -1
induces macrophage infiltration,
induces pro-inflammatory cytokine
secretion

39.53

0.0008

-12.74

0.2549

1.339

0.0217

0.4833

0.4241

neuronal stimulation and plasticity,
food reward (antiinflammatory).Pro-inflammatory
and increased with HFD or
metabolic syndrome

13.71

<0.0001

-8.55

0.0039

aka FAT, transport fatty acids into
and out of wide range of cells.
Inhibited by LPS and HDL, induced
by cholesterol, CSF, IL-4, insulin and
glucose.

47.9

0.0003

-25.13

0.0399

TNF ligand, stimulate T-cell growth
and cytokine synthesis (IL-4 and IL10)

Supplemental Table 2. Hippocampi multiplex genes, function, and
treatment comparisons. Gene functions for the full plex of hippocampi genes
measured is described. Mean difference and p-value for key treatment
comparisons is defined. Statistical significance was calculated using one way
ANOVA.
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